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This first edition of the Global Drug Policy 
Index is dedicated in loving memory 
of Wanjiku Kamau Shelmerdine - 11th 
May 1969 - 7th May 2021. A fearless 
and powerful advocate, who inspired 
and touched the lives of so many. She 
had a deep sense of justice and the 
clarity of vision to know what needed 
to change. For more than two decades, 
she dedicated her sharp intellect and 
exuberant energy towards the fight 
to end HIV – with a strong focus on 
HIV prevention for young women. In 
recent years, she became more involved 
in advocacy for harm reduction and 
drug policy reform - notably laying 
the ground in her home country of 
Kenya. At the global level, Wanjiku was 
deeply supportive of the work of the 
International Drug Policy Consortium and 
our partners. She contributed directly 
to this Index by facilitating the “Co-
Creation” Focus Group Discussions in 
September 2020. With this dedication we 
honour and remember her. Wanjiku – your 
extraordinary light shines on. 
Rest in power.
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For decades, tracking how well - or badly - governments are doing in drug policy 
has been an elusive endeavour. In no small part, this is because data collection 
efforts by both governments and the UN have been driven by the outdated and 
harmful goal of achieving a ‘drug-free society’. The success of drug policies has 
not been measured against health, development and human rights outcomes, 
but instead has tended to prioritise indicators such as the numbers of people 
arrested or imprisoned for drug offences, the amount of drugs seized, or the 
number of hectares of drug crops eradicated.
This wrong-headed focus of drug policy and, as a result, data collection has 
prevented a genuine analysis of whether drug policies have contributed to 
overarching policy goals such as achieving gender equality, reducing stigma 
and discrimination, protecting the rights of Indigenous peoples, or alleviating 
poverty. Marginalised communities who are disproportionately targeted by drug 
policies have remained largely invisible, while in many countries punitive drug 
control measures continue to operate unabated. The net result is that there is a 
severe dearth of accountability when it comes to the repressive approaches to 
drug control that most governments continue to employ.
In this context, it is my absolute pleasure to welcome the first edition of the 
Global Drug Policy Index, a new tool which offers the first-ever data-driven 
global analysis of drug policies and their implementation in a systematic, 
comprehensive and transparent manner. The Index has been developed by civil 
society and community organisations, in partnership with academia. The voice 
and experience of civil society and affected communities is critical for ensuring 
that policies respond to the needs and realities of people on the ground. In the 
worrying current context of shrinking civil society space, this civil society-led 
initiative is to be applauded.
The power of the Global Drug Policy Index lies in its key objective: to score and 
rank how countries are faring in different areas of drug policy as identified in the 
UN report ‘What we have learned over the last ten years: A summary of knowledge 
acquired and produced by the UN system on drug-related matters’,1 and derived 
from the landmark UN System Common Position on Drugs.2 Using 75 indicators, 
the Index covers five dimensions ranging from criminal justice and extreme 
responses, to health and harm reduction, access to medicines, and development.  
Foreword
1 UN system coordination Task Team on the Implementation of the UN System Common Position on drug-
related matters (March 2019), What we have learned over the last ten years: A summary of knowledge acquired 




2 United Nations Chief Executives Board (November 2018), United Nations system common position supporting 





Importantly, the Index seeks to capture drug policies 
in their implementation, rather than looking only 
at what is on paper. Throughout this report, you 
will hear stories from communities who have been 
directly affected by drug policies, often with serious 
and long-lasting effects on their lives and the lives 
of their loved ones. These powerful testimonies 
provide the Index with the nuance and real-life 
experiences that are generally lacking in exclusively 
data-driven research.
The reality that emerges is sobering. Unsurprisingly, 
no country has reached the perfect score. In fact, 
the highest score in this year’s Index - allocated 
to Norway - only reached 74/100. This is because 
despite countries’ commitments to better align 
drug policies with human rights, health and 
development, the destructive power of punitive 
and stigmatising drug laws continues to impoverish 
communities growing plants for illegal drug 
production, prevent people who use drugs from 
accessing life-saving harm reduction services, and 
drive countless acts of police brutality, arbitrary 
deprivation of liberty, torture and killings. 
The Global Drug Policy Index is nothing short of a 
radical innovation. For decision-makers wishing to 
understand the consequences of drug control, as 
well as for those who seek to hold governments 
accountable, the Index sheds light on critical 
aspects of drug policies that have been historically 
neglected, such as the intersection of drug policy 
and development, or the differentiated impacts of 
drug law enforcement on ethnic groups, Indigenous 
peoples, women and the poorest members of 
society. The end goal of the Index is to initiate 
constructive discussions about what needs to 
change, emphasise the importance of evidence- 
and rights-based drug policies, and guide policy 
making priorities and reforms for the years to 
come.
I strongly encourage you to take the time to explore 
the data and stories behind the Index. In the 
meantime, this report will give you a snapshot of 
the key trends, commonalities and discrepancies 
in drug policies and their implementation in the 30 
countries evaluated by the Index for the year 2020. 
The report ends with a series of recommendations 
for policy makers, which align closely with the 
evidence and recommendations promoted by 
the UN. Among other things, the report urges 
governments to end violence, arbitrary detention, 
forced eradication, extreme sentencing and 
disproportionate penalties, and instead promote 
access to health, medicines and harm reduction 
services, as well as a long-term development 
approach for marginalised communities worldwide. 
It is my hope that, in the coming years, the 
Global Drug Policy Index will become a critical 
accountability and evaluation tool for civil society, 
advocates and policy makers alike. The Index will 
encourage governments worldwide to urgently 
reform outdated and ineffective drug policies in 
order to protect the health and human rights of 
everyone in society. 
Credit: Global Commission on Drug Policy 
 
Helen Clark 
Chair of the Global Commission 
on Drug Policy
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The Harm Reduction Consortium
The Global Drug Policy Index is a project of the Harm Reduction Consortium, 
which includes the following partners: the European Network of People Who 
Use Drugs (EuroNPUD), the Eurasian Harm Reduction Association (EHRA), the 
Eurasian Network of People who Use Drugs (ENPUD), the Global Drug Policy 
Observatory (GDPO) / Swansea University, Harm Reduction International (HRI), 
the International Drug Policy Consortium (IDPC), the Middle East and North 
Africa Harm Reduction Association (MENAHRA), the West African Drug Policy 
Network (WADPN), the Women and Harm Reduction International Network 
(WHRIN), and Youth RISE. Special thanks are due to Jamie Bridge (IDPC) for 
coordinating the Harm Reduction Consortium throughout this ambitious 
project.
Donors
This Index has been developed thanks to the timely and invaluable funding 
from the Robert Carr Fund via its Strategic Opportunity Funding.
Index development and data collection 
Methodology and Index development 
Prof Dave Bewley-Taylor and Dr Matthew Wall (GDPO, Swansea University)
Coding team 
Daisy Evans, Fin Oades, Jack Tudor and Ladislav Zeman (Swansea University)
Research on harm reduction funding 
Catherine Cook, Charlotte Davies, Colleen Daniels, Giada Girelli, Naomi Burke-
Shyne, Sam Shirley-Beavan and Suchitra Rajagopalan (HRI)
Civil society survey 
Thanks are due to all 371 civil society experts who filled in the civil society 
survey to assess drug policy implementation in their country.
Scientific Advisory Group 
Prof Alison Ritter (Drug Policy Modelling Program, Social Policy Research Centre, 
University of New South Wales), Prof Cees van der Eijk (Methods and Data 
Institute, the University of Nottingham), Colleen Daniels (HRI), Isabel Pereira 
(Dejusticia), Luciana Pol (CELS), Mat Southwell (EuroNPUD), Nazlee Maghsoudi 
(University of Toronto and Centre on Drug Policy Evaluation), Sandeep Chawla 
(Formerly UNODC, currently retired/independent) and Dr Vivienne Moxham-Hall 
(Policy Institute, King’s College London). 
Communications Advisory Group 
Carolina Ahumada (Youth RISE), Ganna Dovbakh (EHRA), Hasan Fakih 
(MENAHRA), Jake Agliata (INPUD), Jurgita Juozaitytė (EHRA), Marie Nougier 
(IDPC), Michael Kessler (Consultant), Peter Kim (CDPC), Ruby Lawlor (Youth 
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RISE) and Suchitra Rajagopalan (HRI). Special 
thanks are due to Juan Fernández Ochoa (IDPC) for 
coordinating this group.
Index methodology consultations 
Focus group discussions: 
Adria Cots Fernandez (IDPC), Ailish Brennan (Youth 
RISE), Ajeng Larasati (HRI), Ancella Voets (Frontline 
AIDS), Ann Fordham (IDPC), Anna Dovbakh (EHRA), 
Anton Basenko (ENPUD), Beatrix Vas (Youth RISE), 
Catherine Cook (HRI), Chinwike Chijioke Chinwike 
(WADPN), Clemmie James (HPA), Corina Giacomello 
(Equis Justicia para las Mujeres), Daisy Bowdery 
(Youth RISE & IDPC), Damon Barrett (University 
of Gothenburg), Dania Putri (IDPC), Daniel Wolfe 
(OSF), Dave Bewley-Taylor (GDPO), David Subeliani 
(ENPUD), Elie Aaraj (MENAHRA), Eliza Kurcevic 
(EHRA), Ernesto Cortes (LANPUD), Gen Sander 
(HRI), Giada Girelli (HRI), Gloria Lai (IDPC), Hisyam 
Ikhtiar (LBH Masyarakat), Isabel Pereira (Dejusticia), 
Jamie Bridge (IDPC), Jeff Lazarus (IS Global), Joana 
Canedo (Youth RISE), John Walsh (WOLA), Juan 
Fernández Ochoa (IDPC), Julius Togba (WADPN), 
Kunal Naik (Coalition Plus), Lisa Sanchez (MUCD), 
Lt. Abibatu D. Cole (WADPN), Luciana Pol (CELS), 
Machteld Busz (Mainline), Marie Nougier (IDPC), 
Martin Jelsma (TNI), Mat Southwell (EuroNPUD), 
Matthew Kavanagh (HIV Policy Lab), Matthew 
Wilson (OSF), Mauro Guarinieri (INPUD), Mike Trace 
(Rome Consensus Partnership), Nazlee Maghsoudi 
(ICSDP), Olga Belyaeva (ENPUD), Orzala Nemat 
(AREU), Pablo Cymerman (Intercambios), Palani 
Narayanan (Global Fund), Pann Ei Kham (DPAG), 
Penny Hill (Harm Reduction Australia), Prince 
Bull Luseni (WADPN), Robert Csak (HRI), Rui 
Miguel Coimbra Morais (EuroNPUD), Ruth Birgin 
(WHRIN), Sam Shirley-Beavan (HRI), Samuel Ayisi 
(WADPN), Shaun Shelly (TB/HIV Care Association), 
Steve Rolles (Transform Drug Policy Foundation), 
Summer Walker (GI-TOC), Taras Ratushnui (ENPUD), 
Tess Woolfenden (HPA), Thomas Brigden (EJAF), 
Thomas Cai (AIDS Care China), Tripti Tandon 
(Lawyers Collective), Valentin Simionov (INPUD), 
Vicknasingam Balasingam Kasinather (UMMC), 
Victoria Grandsoult (UNITE) and Vielta Parhomenko 
(WHRIN & ENPUD). Thanks are due to Wanjiku 
Shelmerdine for moderating the discussions, and to 
Alexander Soderholm for acting as rapporteur and 
drafting the report of the focus groups discussions.
Expert interviews and discussions:
Brendan Hughes (EMCDDA), Catherine Cook, Robert 
Csak and Sam Shirley-Beavan (HRI), Prof Desmond 
Cohen (Independent), Prof Ken Benoit (London 
School of Economics), Prof Peter Reuter (University 
of Maryland), Phillipa Tucker (Accountability 
International) and Thalia Keohoe Rowden (Human 
Rights Measurement Initiative). Thanks are due 
to Jack Tudor for acting as rapporteur and 
drafting the report of these meetings. Note that 
engagement with the consultation process does not 
indicate endorsement of the project.
UN expert meeting participants and interviewees
Angela Me (UNODC), Annette Verster (WHO), 
Ehab Salah (UNODC), Emily Christie (UNAIDS), 
Fariba Soltani (UNODC), Jane N Batte (UNAIDS), 
Keith Sabin (UNAIDS), Rebecca Schleifer (UNDP), 
Thomas Pietschmann (UNODC) and Zaved 
Mahmood (OHCHR).  Note that engagement 
with the consultation process does not indicate 
endorsement of the project. 
 
Dimension construction and index weighting 
consultations
Adeeba Kamarulzaman (Universiti Malaya & 
International AIDS Society), Ahsan Ahmad 
(Universiti Malaya & Yale University), Axel Klein 
(ECOWAS), Caroline Chatwin (University of Kent), 
Alex Stevens (University of Kent), Catherine 
Appleton (University of Leeds), Catherine Neill 
Harris (Rice University), Coletta Youngers (IDPC), 
Constanza Sanchez (ICEERS), Craig Reinarman 
(University of California Santa Cruz), Damon 
Barrett (University of Gothenburg), David 
Mansfield (Independent Consultant), Diederik 
Lohman (Consultant), Diego Garcia Devis (OSF), 
Dirk van Zyl Smit (University of Nottingham, 
Leverhulme Emeritus Professor), Ediomo-
Ubong Nelson (International Blue Cross/GDPO), 
Gernot Klantschnig (University of Bristol), Gloria 
Lai (IDPC), Heloisa Broggiato Matter (IAHPC & 
Swansea University), John Walsh (WOLA), Julia 
Buxton (University of Manchester), Julie Hannah 
(University of Essex), Karen Joe Laidler (Hong 
Kong University), Katherine Pettus (IAHPC), Khalid 
Tinasti (Graduate Institute), Lisa Sanchez (MUCD), 
Maria-Goretti Loglo (IDPC), Mikhail Golichenko (HIV 
Legal Network), Monica Barrett (RMIT University), 
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Naomi Burke-Shine (HRI), Neil Carrier (University 
of Bristol), Niamh Eastwood (Release), Olivia Rope 
(PRI), Pedro Arenas (Corporación Viso Mutop), Peter 
Sarosi (RRF), Rick Lines (Swansea University), Ricky 
Gunawan (OSF), Steve Rolles (Transform Drug 
Policy Foundation), Summer Walker (GI-TOC), Tripti 
Tandon (Indian Lawyers Collective), Yong-an Zang 
(Shanghai University), Zara Snapp (Instituto RIA) 
and Zoe Pearson (University of Wyoming). 
Story telling
The stories showcased in the Global Drug Policy 
Index were collated thanks to the invaluable 
support of many colleagues from sister 
organisations worldwide. The Harm Reduction 
Consortium is indebted to them and especially 
to the storytellers whose life experiences 




The website for the Global Drug Policy Index was 
designed by Café. 
 
Analytical report
This report was drafted by Marie Nougier and 
Adria Cots Fernandez (IDPC). The authors wish to 
thank the following reviewers for their valuable 
inputs and comments: Ann Fordham, Jamie Bridge,  
Juan Fernandez Ochoa (IDPC), Dave Bewley-Taylor 
and Matthew Wall (GDPO, Swansea University), 
Catherine Cook, Colleen Daniels, Giada Girelli and 
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Colombia#21 40 62 36 36 43 23
Jamaica#15 48 76 65 19 35 39
Thailand#24 36 38 28 31 34 48
Senegal#10 53 91 31 45 43 N/A
Morocco#11 51 91 31 43 36 N/A
Hungary#12 50 79 41 29 48 N/A
Lebanon#15 48 58 37 50 45 N/A
South Africa#17 47 80 39 37 29 N/A
India#18 46 63 38 49 33 N/A
Argentina#19 44 76 24 26 48 N/A
Mozambique#21 40 86 23 21 29 N/A
Mexico#26 35 47 32 36 26 N/A
Kenya#27 34 54 13 46 23 N/A
Indonesia#28 29 35 27 23 31 N/A
Uganda#29 28 59 17 13 21 N/A
Brazil#30 26 45 20 9 31 N/A
Kyrgyzstan#12 50 82 37 42 39 N/A
Costa Rica#9 54 82 51 24 59 N/A
Georgia#7 55 89 25 51 55 N/A
North Macedonia#7 55 74 38 46 61 N/A
Canada#6 56 78 34 54 56 N/A
Australia#5 65 85 54 60 60 N/A
UK#4 69 92 50 64 69 N/A
Portugal#3 70 86 64 61 68 N/A
New Zealand#2 71 88 58 58 78 N/A
Norway#1 74 91 49 74 81 N/A
Afghanistan#14 49 62 32 50 55 47
Russia#20 41 67 34 33 28 N/A
Nepal#21 40 68 30 36 25 N/A
Ghana#24 36 71 28 12 32 N/A
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What is the Global Drug Policy Index?
The Global Drug Policy Index is a unique tool that documents, measures and 
compares national-level drug policies, providing each country with a score and 
ranking that shows how much their drug policies and their implementation 
align with the UN principles of human rights, health and development. As such, 
the Index provides an essential accountability and evaluation mechanism in 
the field of drug policy. It is composed of 75 indicators running across 5 broad 
dimensions of drug policy. This first iteration evaluates the performance of 30 
countries covering all regions of the world.
Key takeaways from the 
Global Drug Policy Index
1. The global dominance of drug policies based on repression and punishment has led to low 
scores overall, with a median score of just 48/100, and the top-ranking country (Norway) only 
reaching 74/100.
2. Standards and expectations from civil society experts on drug policy implementation vary 
from country to country.
3. Inequality is deeply seated in global drug policies, with the top-ranking 5 countries scoring 
3 times as much as the lowest-ranking 5 countries. This is in part due to the colonial legacy of 
the ‘war on drugs’ approach. 
4. Drug policies are inherently complex: a country’s performance in the Index can only be fully 
understood by looking across and within each of the dimensions.
5. Drug policies disproportionately affect people marginalised on the basis of their gender, 
ethnicity, sexual orientation and socio-economic status.
6. There are wide disparities between state policies and how they are implemented on the 
ground.
7. With a few exceptions, the meaningful participation of civil society and affected 
communities in drug policy processes remains severely limited.
The Global Drug Policy Index 2021
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Absence of extreme 
sentencing and responses
The use of extreme and rights-violating forms 
of state power constitutes an integral part of 
many states’ responses to drugs. This includes 
the imposition of the death penalty for drug 
offences (reported in 3 countries: India, Indonesia 
and Thailand), extrajudicial killings (perceived 
as occurring regularly in 6 countries, being 
‘widespread’ in Mexico, and ‘endemic’ in Brazil), 
and militarised drug law enforcement (reported as 
prevalent in at least 14 countries). In almost half 
of the countries covered in the Index, drug laws 
and policies allow for life imprisonment for drug-
related offences, while the involuntary confinement 
of people who use drugs as a form of ‘treatment’ 
is a widespread phenomenon (reported to varying 
degrees in 25 of the 30 countries studied here). 
Proportionality of the criminal 
justice response
The Index emphasises the extensive human 
rights abuses within the criminal justice 
apparatus committed in the name of drug 
control, including acts of violence and torture 
by the police (considered as rare occurrences 
in only 6 out of the 30 countries), and cases 
of arbitrary arrests and detention (considered 
as rare in only 3 countries). Fair trial rights are 
reported as severely restricted in 13 countries. 
The criminal justice response to drugs was 
perceived as disproportionately impacting specific 
ethnic and gender groups in various countries, 
and as particularly affecting low-income groups 
across all 30 countries. Finally, despite efforts 
made by 8 countries to decriminalise drug use 
and possession and by 29 countries to provide 
alternatives to prison and punishment, most 
people targeted by the criminal justice system are 
involved in non-violent offences. In parallel, while 
none of the 30 countries have mandatory pretrial 
detention, 24 of them impose mandatory minimum 
penalties for drug offences, most of which can be 
applied for first-time offences.
Health and harm reduction
Positively, most countries’ policy and strategy 
documents  explicitly support harm reduction. 
However, implementation is a cause for concern. 
Funding for harm reduction services is considered 
to be adequate in only 5 out of the 30 countries 
included in the Index; alarmingly, in 15 countries 
the current levels of funding are projected to 
decrease in the next 3 to 5 years. The Index also 
reveals a shocking lack of availability and coverage 
of harm reduction interventions, with widespread 
access to needle and syringe programmes (NSPs) 
only reported in 5 countries covered by the Index, 
opioid agonist treatment (OAT) in 4 countries, 
peer distribution of naloxone in 3, and no country 
reporting wide coverage of drug checking services. 
Access to harm reduction services is considered 
to be particularly restricted in an overwhelming 
majority of countries for people discriminated 
against on the basis of ethnicity, gender identity 
and sexual orientation.
Access to controlled medicines
Although all but 2 countries (Kenya and Morocco) 
explicitly recognise the obligation to ensure 
access to controlled medicines within their 
national legislation or policy documents, states’ 
performance in ensuring actual availability on 
the ground remains very poor for two thirds of 
the countries studied in the Index. Availability 
and access for those in need remain particularly 
concentrated in Global North countries. The Index 
also underscores differences in access within each 
country, with geographical location and socio-
economic status – and to a lesser extent gender 
and ethnicity – playing a major role in people’s 
ability to access controlled medication.
Development
Four of the 30 countries were evaluated under 
this dimension - Afghanistan, Colombia, Jamaica 
and Thailand - all of which achieved relatively 
poor results. The data show that alternative 
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development remains entrenched in a security and crop eradication approach. 
This is despite the efforts made by some countries to embed their alternative 
development programmes into a broader development strategy, or to take 
into account considerations like environmental protection. Ensuring adequate 
sequencing within alternative development programmes remains an elusive 
endeavour for most countries, with the exception of Afghanistan which was 
reported as taking this factor into consideration more seriously. Similarly, 
the level of involvement of affected communities in alternative development 
programmes remains disappointing, except in Thailand where efforts are being 
made in that regard. Overall, the benefits of alternative development policies 
and programmes for women, young people and low-income groups were 
reported as being limited in Colombia, Jamaica and Thailand, and moderate in 
Afghanistan.
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What is the Global Drug Policy Index?
The Global Drug Policy Index is the first ever composite index that 
documents, measures and compares national-level drug policies. As such, 
it is a unique tool that provides each country with a score and ranking that 
shows how much national drug policies and their implementation align with 
the principles of human rights, health and development. Its indicators and 
dimensions are drawn from the ‘United Nations System Common Position 
supporting the implementation of the international drug control policy 
through effective inter-agency collaboration’3 and its implementation Task 
Team’s report ‘What we have learned over the last ten years: A summary 
of knowledge acquired and produced by the UN system on drug-related 
matters’.4 The Index draws its data from desk-based research on existing 
national laws and policies, as well as a comprehensive civil society survey 
to assess policy implementation on the ground for the year 2020.
Why do we need such an index?
This Index was developed in a context where differences in government 
approaches to drug policies have reached a breaking point: while the use 
of certain drugs is legal in one country, being in possession of the same 
substances elsewhere is met with compulsory detention, life imprisonment 
or even death. These differences are not reflected in the resolutions of the 
UN Commission on Narcotic Drugs, which are all adopted by consensus 
amongst member states. In addition, existing tools that track global trends 
in drug markets and drug policy mostly focus on indicators related to drug 
law enforcement (arrests, seizures, incarceration) and eradication efforts 
- providing an incomplete and skewed picture of drug policies. These tools 
also tend to rely almost exclusively on government data that have varying 
levels of reliability.
The Global Drug Policy Index seeks to fill an important gap by providing 
a unique accountability and evaluation mechanism that describes and 
assesses national drug policies and their implementation, using existing 
data complemented by civil society research and insights, and focusing on 
5 broad dimensions of drug policy related to health, human rights, criminal 
justice and development.
Introduction
3 United Nations Chief Executives Board (November 2018), United Nations system common position 




4 UN system coordination Task Team on the Implementation of the UN System Common Position on 
drug-related matters (March 2019), What we have learned over the last ten years: A summary of knowledge 
acquired and produced by the UN system on drug-related matters, 
https://www.unodc.org/documents/commissions/CND/2019/Contributions/UN_Entities/What_we_have_
learned_over_the_last_ten_years_-_14_March_2019_-_w_signature.pdf
5 Ibid, p. 4
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Who is the Index for? 
The overall objective of this Index is to map the 
range of drug policy responses around the world, 
to identify key aspects of drug policy that require 
urgent attention, to facilitate discussions on options 
for drug policy reform, and to guide policy making 
priorities and reforms at the national level.
For governments, the Index is a useful evaluation 
mechanism to track progress towards aligning their 
drug policies with UN standards, and to respond 
to some of the key concerns from civil society 
and academia about current policies and their 
implementation. The Index can also be used to 
learn from the experiences of other countries that 
have been allocated a higher (or lower) score.
For UN agencies, the Index can become an 
invaluable tool to measure progress towards 
the alignment of national drug policies with the 
recommendations included in the UN System 
Common Position on drug-related matters, as well 
as in international human rights law and standards. 
For civil society and community networks, the 
Index can become an invaluable tool to measure 
progress towards the alignment of national drug 
policies with the recommendations included in 
the UN System Common Position on drug-related 
matters, as well as in international human rights 
law and standards. 
For the media, the Index includes critical data, 
as well as stories and lived experiences of 
communities on the ground, which can be used to 
inform high-quality coverage of drug policy issues. 
What are we measuring?
The Global Drug Policy Index measures how drug 
policies align with the recommendations included 
in the UN report ‘What we have learned over the 
last ten years: A summary of knowledge acquired 
and produced by the UN system on drug-related 
matters’. It is composed of 75 indicators that run 
across 5 dimensions:
The absence of extreme sentencing and responses: 
This dimension covers the use of the death penalty, 
extrajudicial killings, militarised policing, life 
sentencing and non-consensual confinement.
The proportionality of the criminal justice 
response: This dimension focuses on human rights 
violations in the criminal justice system, the use 
of mandatory sentencing and pre-trial detention, 
decriminalisation and other alternatives to arrest, 
prosecution, conviction and punishment, the extent 
of imprisonment for non-violent drug offences, and 
expert’s perception on the differentiated impact 
of the criminal justice response on women, ethnic 
groups and people living in poverty.  
Health and harm reduction: In this dimension, we 
assess the extent to which state policies prioritise a 
harm reduction approach for people who use drugs, 
harm reduction funding, availability and coverage of 
services, as well as experts’ perception on equity in 
access to services for specific groups.
Availability of, and access to, internationally 
controlled substances for the relief of pain and 
suffering: This dimension evaluates whether 
access to medicines is prioritised in government 
policies, whether controlled medicines are actually 
available and accessible, and perceptions as to 
whether specific groups have equitable access to 
controlled medicines.
‘[The Task Team report] is a collection of successful experiences in law enforcement, prevention, health care, 
human rights and development over the last ten years. It is a tool for sharing best practices and promoting 
evidence-based, rights-based approaches’
António Guterres, Secretary-General of the United Nations5
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Development: This last dimension is used 
for countries where there are alternative or 
sustainable development policies in place to 
provide alternatives to the cultivation of crops 
used for illegal drug production. It focuses on 
whether such countries have an alternative 
development policy, how crop eradication is 
managed, and experts’ perception of how effective 
alternative development policies are for key 
beneficiaries, including women, young people and 
Indigenous groups.
The Global Drug Policy Index does not seek to 
measure the impact of the COVID-19 pandemic 
on drug policies or on affected communities. The 
disruption brought about by the pandemic is a 
singular occurrence that began in early 2020 and 
that - while still ongoing - is likely to subside 
in the long term. Therefore, indicators explicitly 
focused on COVID-19 may not be replicable in 
future iterations of the Index. Furthermore, lack 
of pre-2020 data would make it impossible to use 
this edition of the Index to accurately assess the 
differential impact of the pandemic. 
Likewise, the Global Drug Policy Index does not 
measure the establishment, characteristics, or 
implementation of legally regulated markets of 
internationally scheduled drugs for adult non-
medical use (e.g., Canada’s regulated cannabis 
market). This is because legal regulation is not 
discussed in the UN System Common Position on 
drug-related matters or its implementation Task 
Team’s report; and according to our methodology, 
only policies included in the Task Team report are 
reflected in the Index. Country scores are therefore 
not being impacted by the presence, or absence, of 
regulated markets for certain drugs. 
Throughout this report we use median values to 
capture the middle or typical performance of a 
country included in the Index, and to contrast 
it with the results achieved by other countries. 
For each data set generated by the Index – for 
instance, the global ranking of the 30 countries – 
the median is the middle number in that series. 
It is worth noting that, in some policy clusters, 
more than half of the countries have achieved very 
extreme scores, which in turn results in very high 
or very low median values. For instance, because 
27 out of the 30 surveyed countries have abolished 
the death penalty for drug offences, the median 
value in that policy cluster is 100/100, even though 
3 countries retain capital punishment for drug 
offences, and the mean average value is 91.93/100. 
In the opposite direction, the median value of the 
decriminalisation cluster is 0/100, as 20 out of the 
30 countries have failed to decriminalise the use 
and possession for personal use of any drug. This 
tells us that the ‘typical’ country in the Index has 
abolished the death penalty for drug offences, but 
has not decriminalised any form of drug use or 
possession for personal use.
This first edition of the Index covers 30 countries 
from all regions of the world: Afghanistan, 
Argentina, Australia, Brazil, Canada, Colombia, 
Costa Rica, Georgia, Ghana, Hungary, India, 
Indonesia, Jamaica, Kenya, Kyrgyzstan, Lebanon, 
Mexico, Morocco, Mozambique, Nepal, New 
Zealand, North Macedonia, Norway, Portugal, 
Russia, Senegal, South Africa, Thailand, Uganda and 
the United Kingdom. This list will be expanded in 
future iterations of the Index.
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About this report
This report provides an overview of the Index results regarding key trends, 
commonalities and differences in drug policies and their implementation in 30 
countries, reviewing data from 2020. The report starts with a global review of 
the results, assessing data on each of the dimensions in turn. We then provide 
a snapshot of the results for each of the 30 countries in the form of visual 
factsheets. A comprehensive description of the methodology is available on the 
Index website, alongside all of the data and stories that underpin this report.
Map the range of drug policy 
responses around the world
Identify key aspects of drug 
policy needing urgent action
Facilitate discussions on 
reform options
Guide national-level policy 
making priorities and 
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Methodology
How was the Index developed? 
The Global Drug Policy Index was developed through a five-step process. 
The first step consisted in expert consultations, including semi-structured 
interviews with experts in drug policy analysis and advocacy as well as from 
other composite index projects; workshops with drug and data experts from 
civil society and UN agencies; regular calls with media and dissemination 
specialists, with the formation of a Communications Advisory Group; and an 
online workshop with participants of the semi-structured interviews to reflect 
on the Index development team’s analysis and findings. 
Interim reports were then produced,7 outlining key findings from the 
consultation process. In this second phase, the normative documents that were 
to form the basis of the Index indicators and dimensions (i.e. the UN System 
Common Position on drug-related matters and associated Task Team report) 
were selected, a Scientific Advisory Group (SAG) was established to support the 
Index development team throughout the process, and a work programme was 
drafted for indicator selection and Index development. 
Third, the Index development team, in consultation with the SAG, worked on 
consolidating the methodology by analysing the UN documentation to identify 
relevant policy recommendations, creating a coding approach and an expert 
survey to capture indicators relevant to these recommendations, and developing 
a process for generating aggregation rules and weights to drive the Index. 
In the fourth phase, the data were collected. This included a desk-based 
analysis of countries’ drug policy frameworks by the coding team at Swansea 
University, a survey of civil society experts across the 30 countries covered by 
the Index, an international survey of drug policy analysts to create indicator 
weights, and a ‘Delphi’ process8 for the SAG to agree on cluster and dimension 
weights.
The fifth and final step focused on data analysis, including integrating all data 
collected to produce Index scores, verifying the robustness and sensitivity of 
the Index, and analysing the survey data to rule out systematic biases. The 
scores, data and full methodology are published on the Index website and 
reflected in this report.
7 Soderholm, A. (November 2020), GDPI “Co-creation” focus groups: Summary report, ADD LINK TO THE 
REPORT; Tudor, J. (January 2021), Global Drug Policy Index expert interview report: Obstacles, solutions, and the 
path forward, ADD LINK TO THE REPORT
8 The term ‘Delphi method’ refers to a framework for aggregating diverse perspectives based on the results 
of multiple rounds of questionnaires sent to a panel of experts where, after each round, the experts are 
presented with an aggregated summary of the panel’s responses. This is done to allow each expert to adjust 
their answers in the light of the panel’s group response when undertaking subsequent rounds. In devising 
weights for the GDPI, we conducted three rounds of weighting with SAG members and disseminated panel 
data between each round. In advance of the final round, we also held a discursive session via Zoom with the 
panel to ensure that the substance of disagreements on weights as well as the aggregated summary were 
shared with all members. 
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How was the data compiled? 
In order to arrive at an index like the Global Drug 
Policy Index, it is necessary to aggregate a range of 
indicators into a single score. There are two types 
of data involved in such an endeavour: indicator-
level data (i.e., data on each state’s performance 
on drug policy indicators) and weighting data (i.e., 
data that captures the relative contribution of each 
indicator to the final score).
Drug policy is both complex and multifaceted. 
Furthermore, the Global Drug Policy Index is 
designed to allow its users both to rank states’ 
overall performance and to undertake more fine 
grained analysis of specific areas of drug policy. 
With this in mind, an approach was developed 
that builds from the indicators upwards into 3 
successive layers of aggregation:
Indicator data: 75 policy indicators. Data were 
collected for the 75 policy indicators with a focus 
both policy in law and policy in implementation. 
This was achieved through a combination of a 
systematic coding process and a survey of drug 
policy experts from civil society. The systematic 
coding process was led by the coding team at 
Swansea University and was conducted via desk-
based research. This resulted in the creation of a 
series of original data points as well as drawing 
on existing data including from the World Bank 
and Harm Reduction International. The survey 
was developed by the Methodology and Index 
Development team and was shared with civil 
society experts in each of the 30 countries covered 
by the Global Drug Policy Index. 371 civil society 
experts responded to the survey, and the median 
responses of these country experts (weighted by 
their confidence in assessing each policy area) are 
used to categorise each state on a range of aspects 
of drug policy. 
Weighting data 1: 21 policy clusters. The 75 
indicators are grouped into 21 thematic policy 
clusters. Each cluster score reflects a combination 
of indicator scores ranging from 0 to 100. The 
weighting for each indicator within each cluster 
was determined through an international survey of 
34 drug policy analysts. 
Weighting data 2: 5 policy dimensions. The 21 
policy clusters are grouped into five overarching 
policy dimensions, each with a score ranging from 
0 to 100. The score on each dimension is calculated 
according to the weighted average of the relevant 
cluster scores. The importance of each policy 
cluster to each dimension was determined through 
a ‘Delphi’ weighting exercise with the SAG.
Weighting data 3: 1 country score. Each country 
is then given a total score ranging from 0 to 100. 
The score represents the weighted average of all 
relevant policy dimension scores. The importance 
of each dimension was determined through a 
‘Delphi’ weighting exercise with the SAG.
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Limitations 
The relative paucity of objective, comparable 
data on many of the most important aspects of 
drug policy created a significant challenge for this 
project: while it is possible to objectively verify 
formal/legal aspects of drug policy, many of the 
significant recommendations of the UN System 
Common Position on drug-related matters and 
associated Task Team report centre on (or at least 
require) effective implementation. 
In responding to this challenge, a ‘mixed methods’ 
research design was developed, drawing on 
the perceptions of individuals with specialist 
knowledge of drug policy in each country to 
complement the coding of countries’ formal/
legal policies. While the approach to survey 
design included extensive guidelines for each 
question in order to minimise cultural differences 
in interpretation, it is likely that some deep-
seated cross-national differences in perceptions 
surrounding issues such as racial and gender-based 
discrimination, levels of police violence and so 
on are expressed in the data that relies on expert 
perceptions.
Furthermore, we were unable to measure every 
aspect of drug policy that we might have liked to. 
This is partly because of the scope and complexity 
of the project: the Global Drug Policy Index is global 
both in the range of states covered and in the 
aspects of drug policy considered. In reality each 
of the dimensions of drug policy captured in the 
Index would be candidates for their own indices. In 
some instances (for example, prevention policy), a 
lack of data availability and the difficulty inherent 
in evaluation meant that a policy area identified 
within the project’s foundational documents does 
not feature in this iteration of the Global Drug Policy 
Index. In other areas, such as harm reduction, we 
chose to focus on widely-accepted interventions 
about which reliable data already exists, while paying 
less attention to other interventions.
Finally, it is, of course, inevitable that there is a 
loss of fidelity when reducing complex political and 
societal phenomena to numerical representations. 
Moreover, as with indicator selection, the 
methodology inexorably involves a series of trade-
offs.9 It is our hope, however, that this process 
is worth the endeavour in that it facilitates 
comparative and within-country insights about 
the state and future of drug policy that might have 
otherwise proven elusive. The final tally of 75 drug 
policy indicators over 30 countries is the outcome 
of an attempt to create an index that is ‘simple’ 
(i.e., transparent and intuitive) without being 
‘simplistic’ (i.e., overly reductive). Others may have 
chosen a different balancing point, and it is hoped 
that this first iteration of the Global Drug Policy 
Index will spur debate and engagement on how 
best to capture and compare states’ drug policies.
How were the 30 countries 
selected?
In this first iteration of the Global Drug Policy 
Index, resource limitations necessitated the 
decision to focus on the development of a solid 
methodology, and on a realistic number of 
countries (30), as a proof of concept. In order to 
ensure the geographical spread of those countries, 
we employed the regional groupings used by the 
United Nations Office on Drugs and Crime.10 For 
each of the 17 sub-regions, the Harm Reduction 
Consortium, with support from additional civil 
society partners in selected regions, agreed upon 
between one and four countries on the basis of 
three criteria: 1- relevance of drug policy for the 
selected country; 2- data availability on drugs 
and drug policy in the selected country; and 3- 
presence of civil society organisations working on 
drug policy advocacy, alongside a risk assessment 
of whether utilising the Index might make them 
targets of reprisals by their government.11
9 Organisation for Economic Co-operation and Development (OECD), Handbook on Constructing Composite Indicators: Methodology and User Guide, 
2008, https://www.oecd.org/els/soc/handbookonconstructingcompositeindicatorsmethodologyanduserguide.htm
10 Please note that for the purposes of the Global Drug Policy Index, the four subregions of Australia and New Zealand, Polynesia, Melanesia and 
Micronesia were merged into a single ‘Oceania’ region. For more information on the UNODC’s regional groupings, see: United Nations Office on 
Drugs and Crime (2021), ‘Booklet 1. Executive summary, policy implications’, World Drug Report 2021, pp. 81-82, 
https://www.unodc.org/res/wdr2021/field/WDR21_Booklet_1.pdf 
11 Please note that the selection of Afghanistan was made several months prior to the military offensive by the Taliban in August 2021
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What’s next for the Global Drug Policy Index? 
The methodology and data for this first iteration of the Global Drug Policy Index 
will be published in a peer reviewed scientific journal. Importantly, as this first 
edition of the Global Drug Policy Index is being finalised, we are already looking 
to the future. We are currently seeking additional funding to produce new 
iterations of the Index on a biennial basis, with additional countries being added 
to the current 30 for each iteration. As drug policy reforms unfold globally, in 
particular in the area of legal regulation and others, more indicators may be 
included and our methodology be revised to reflect those changes.
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Key takeaways  
1st takeaway: Drug policies based on repression and punishment lead to overall 
low scores 
Most countries’ drug policies are misaligned with governments’ obligations 
to promote health, human rights and development, and continue to rely on 
criminalisation, interdiction, forced eradication and police interventions as a 
form of drug control. This, as a result, hampers access to harm reduction and 
controlled medicines for those in need, and too often results in cases of abuse, 
violence and human rights violations for affected communities. It is particularly 
telling that the highest ranking country, Norway, is only allocated a score of 
74/100, and that the median score is only 48/100 across all 30 countries. 
Global overview
The median scores for each of the dimensions range from 34/100 for the 
proportionality of the criminal justice response, all the way to 76/100 for the 
absence of extreme sentencing and responses. The higher median score recorded 
for the latter, however, should not be seen as evidence that countries are doing 
particularly well on their human rights response. In fact, the data from the Index 
show that a significant cluster of countries continues to pursue extreme rights-
violating policies as a means to control drugs. The higher results for this first 
dimension merely reflect the fact that countries automatically score 100/100 if a 
specific policy is not included in their drug legislation or policy documents. 
2nd takeaway: Standards on drug policy implementation vary from country to 
country 
As explained in the methodology section, a significant share of the data on 
drug policy implementation has been collected via a survey of in-country civil 
society experts. Efforts were made to account for, and reduce the level of, 
cross-national differences in the interpretation of the questions and possible 
responses. However, standards will inevitably vary from one country to another 
- reflecting differing expectations, aspirations and resources in different social 
and political settings. While in some contexts civil society may score their 











country’s performance severely on certain issues, 
in others the perception of country performance 
may be more lenient - with knock-on impacts on 
the overall Index results. 
Cross-national differences in standards are 
perhaps most visible in experts’ perceptions of the 
impacts of equity and drug policies. For instance, 
the fact that Australia, Canada or Colombia obtain 
a much lower score than countries like Afghanistan, 
Lebanon or the United Kingdom on the policy 
cluster concerning perceptions of equity in access 
to harm reduction might not necessarily mean 
that people from marginalised groups in these 3 
countries have significantly less access to harm 
reduction services than in the other 3 countries. It 
might instead underscore the fact that, in the first 
group of countries, there is a larger gap between 
drug policies and the standards and expectations 
of civil society experts.
3rd takeaway: Global inequality extends to drug 
policies 
In addition to the low scores achieved across the 
board, the Index reveals a deep divide in states’ 
approaches to drugs. The average score obtained by 
the top 5 countries – which place greater emphasis 
on human rights, harm reduction and health – is 
almost double the median score of the whole Index, 
and three times the average score achieved by the 
lowest-ranking 5 countries. Given that all people are 
equally entitled to the full enjoyment of their health 
and human rights, no matter where they are from or 
how they are involved with the illegal drug trade, this 
fracture is deeply concerning.
Global inequities, in part due to the legacy of 
colonialism, play a significant role in explaining 
this situation. The devastating long-term impacts 
of colonialism are both magnified and exemplified 
by the global drug control regime’s reliance on 
punitive and stigmatising approaches to drugs. 
These differentiated impacts must be considered 
and addressed, including through demands for 
policy reform and reparations.
While acknowledging these realities, the high 
score achieved by some ‘Global South’ countries 
on certain policies (for instance, Jamaica ranks 
1st in the dimension on proportionality of the 
criminal justice response) shows that this trend 
can be successfully reversed. In that regard, 
the Index shows that it is in the interest of 
communities worldwide to divest from costly and 
counterproductive drug law enforcement measures, 
reform damaging and disproportionate laws, and 
redirect investment in health-focused social and 
community programmes.
4th takeaway: The complexity of drug policy 
Drug policies are intrinsically complex, and 
countries’ performance in one dimension of drug 
policy may not necessarily mirror how well they are 
doing in another. Senegal, for instance, is allocated 
the second highest score with regards to extreme 
sentencing, but only ranks in 18th position on the 
proportionality of its criminal justice response, and 
15th position on access to controlled medicines. 
Similarly, while Jamaica is one of the worst scoring 
countries on its harm reduction response (ranking 
in 27th position), it ranks 1st in terms of the 
proportionality of its criminal justice response. 
And the complexity does not end there. Within 
each of the dimensions, the Index underscores how 
certain countries fare well in some aspects of their 
drug policy, but fail in others. The United Kingdom 
is emblematic of this. While the country scores the 
highest (84/100) on avoiding police abuses, arbitrary 
arrests and detentions, and ensuring fair trial rights, 
it is one of the lowest-ranking countries regarding 
experts’ perception of the disproportionate impacts of 
the criminal justice response on women, marginalised 
ethnic communities and low-income groups. 
5th takeaway: The disproportionate impacts of 
drug policy on specific groups 
The Index highlights that drug policies 
disproportionately impact people from specific 
groups, be it because of geographical location, 
gender, sexual orientation, ethnicity or socio-
economic status. People from low-income groups 
were reported as being disproportionately targeted 
across dimensions, and in particular in the criminal 
justice response where such discriminations are 
reported in every single country covered by the 
Index. With regards to gender, the disproportionate 
impacts of drug control are particularly striking 
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in Latin American countries, especially when it 
comes to criminal justice responses and access to 
controlled medicines. As for ethnicity, Brazil and 
Canada are both singled out as countries where 
such discriminations are reported across the board. 
Furthermore, although all people in contact, 
or associated, with the illegal drug market are 
severely impacted by drug policy, the Index 
underscores how people who use drugs continue 
to be discriminated against by drug policies across 
the world. This ranges from the ongoing lack of 
access to life-saving harm reduction services, to 
discriminations in access to controlled medicines 
for pain relief, widespread criminalisation and 
incarceration, cases of police abuse, arbitrary 
arrests and detention, and forced detention in the 
name of drug ‘treatment’.
6th takeaway: Addressing the gap between policy 
and implementation 
There are wide disparities between state policies 
and how they are being implemented on the 
ground. This is particularly the case in the area of 
health. While all countries included in the Index 
(except for Kenya and Morocco) have recognised 
their obligation to ensure the availability of 
controlled medicines within their policy documents, 
less than a third of these countries scored above 
50/100 on actual access for people that need 
them. The gap between policy and access is yet 
again obvious for harm reduction: while almost two 
thirds of countries do recognise the importance 
of harm reduction ‘on the books’, only a handful 
ensure sufficient coverage of harm reduction 
services. 
A similar trend can be seen for decriminalisation 
and alternatives to prison and punishment. With 
regards to decriminalisation, only a few countries 
have succeeded in removing severe punishment 
and diverting people away from the criminal 
justice system. Similarly, while all countries 
(except for Mozambique) have adopted some form 
of alternative to incarceration or punishment, 
only a handful of countries offer a wide range of 
treatment and care options tailored to the needs 
of people with drug dependence caught in the 
criminal justice system. And the impacts on the 
ground are clear: most people targeted by the 
criminal justice apparatus in drug control efforts 
are perceived by civil society experts as being 
involved in non-violent offences in 23 out of the 30 
countries included in the Index. 
7th takeaway: Poor involvement of civil society 
and communities in drug policy processes 
Our final takeaway relates to the fact that civil 
society and affected communities are rarely 
meaningfully involved in policy making and 
implementation. Although civil society involvement 
was not included as a dimension for the Index, 
various indicators assess the extent of their 
engagement in several drug policy processes. 
In most cases, such involvement was reported 
as being ‘limited’ or ‘very limited’, with only a 
few notable exceptions: Thailand in the area of 
alternative development; Nepal and New Zealand 
regarding access to controlled medicines; and 
Afghanistan, Australia, Canada, India, Mexico, 
Norway and the United Kingdom on peer 
distribution of naloxone.
12 United Nations Chief Executives Board (November 2018), United Nations system common position 
supporting the implementation of the international drug control policy through effective inter-agency 
collaboration, CEB/2018/2,  https://unsceb.org/sites/default/files/2021-01/2018%20Nov%20-%20UN%20
system%20common%20position%20on%20drug%20policy.pdf 
13 UN system coordination Task Team on the Implementation of the UN System Common Position on drug-
related matters (March 2019), What we have learned over the last ten years: A summary of knowledge acquired 
and produced by the UN system on drug-related matters,  https://www.unodc.org/documents/commissions/
CND/2019/Contributions/UN_Entities/What_we_have_learned_over_the_last_ten_years_-_14_March_2019_-
_w_signature.pdf 
14 There are no arbitrary arrests, the courts are competent, independent and impartial, and hearings 
and trials generally follow arrest and charge within a reasonable time. See the World Bank’s TCdata360 
definition of a fair trial:  https://tcdata360.worldbank.org/indicators/hd45eb4d6 
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Policy recommendations 
What would a perfect score look like? 
In order to obtain a score of 100/100 in the Global Drug Policy Index a 
country would need their drug policy and practice to be aligned with the 
recommendations contained within the UN System Common Position on drug-
related matters12 and its implementation Task Team’s report.13 These include:
The absence of extreme sentencing and responses
• The country has abolished the death penalty, including for drug offences. 
All existing death sentences for drug offences have been reviewed and 
commuted.
• The country has taken appropriate measures to ensure that no extrajudicial 
killings are committed in connection to drug control, either by law 
enforcement agents, the military or non-state actors. 
• Military and special security forces are excluded from all tasks pertaining to 
the enforcement of drug laws.
• National drug laws do not allow for life imprisonment as a possible 
sanction for any drug offence. All existing life sentences for drug-related 
offences are reviewed and commuted.
• No person is held against their will in state-run or private drug ‘treatment’ 
centres. Access to inpatient drug treatment is always voluntary. 
The proportionality of the criminal justice response 
• There are no reported cases of violence or torture by the police, or arbitrary 
arrests and detention. All elements of a fair trial14 are respected.
• Criminal justice responses related to drug control do not disproportionately 
impact people on the basis of their ethnicity, gender, sexual orientation or 
socio-economic status.
• The country’s drug laws or legal frameworks do not include mandatory 
minimum sentencing or pretrial detention for drug offences.
• There are provisions in national legislation or in official national policy 
documents for the decriminalisation of all drug use and possession for 
personal use. Where administrative sanctions are applied, these are 
proportionate and non-intrusive. Decriminalisation has led to a dramatic 
reduction in the number of people who use drugs in contact with the criminal 
justice system.
• There are also provisions in national laws and policies for alternatives 
to arrest, prosecution, conviction and/or punishment for drug offences. 
Alternatives exist at the point of initial contact with law enforcement, 
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before conviction and at sentencing. They include a range of treatment and 
care options adapted to the needs and preferences of people dependent on 
drugs caught in the criminal justice system. Failure to attend or complete 
treatment, or restarting/continuing the use of drugs, does not result in 
punishment. 
• People are never, or very rarely, imprisoned for non-violent drug offences, and 
make up less than 5% of the prison population. 
Health and harm reduction
• There are explicit supportive references to harm reduction in national policy 
documents.
• Funding for harm reduction is considered to be adequate and sustainable.
• People who use drugs have adequate access to key harm reduction 
interventions such as NSPs, OAT, take-home naloxone, drug consumption 
rooms and drug checking services, both in the community and in prison.
• There are no disparities in access to harm reduction services on grounds of 
ethnicity, gender, sexual orientation or socio-economic status.
Availability of, and access to, internationally controlled substances for the 
relief of pain and suffering
• There are explicit provisions in national legislation, policy documents and 
regulatory instruments that establish the country’s obligation to ensure 
adequate availability of controlled medicines.
• There is an approved national medicines strategy that recognises the 
importance of availability and accessibility for controlled medicines.
• The policy-making process relating to controlled medicines meaningfully 
involves key stakeholders, such as medical boards, health professionals, 
patients, and patients’ representatives.
• Opioid medicines are available to all those in need for the relief of pain and 
suffering.
• There are no disparities in access to controlled medicines based on 
geographical location, gender, ethnicity and socio-economic status, or for 
people who use drugs.
Development
• Alternative development policies are embedded within a broader 
development strategy that does not operate within a militarised or security 
framework, placing emphasis instead on environment protection, and the 
empowerment of women, youth and low-income groups.
• Alternative development programmes do not include provisions for forced 
eradication and/or the use of aerial spraying. They should allow for adequate 
sequencing to ensure that targeted households have sustainable livelihoods 
in place prior to any crop eradication effort.
• Local communities, minority and indigenous groups are meaningfully involved 
in the design, implementation, monitoring and evaluation of alternative 
development programmes.
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The absence of extreme 
sentencing and responses
The use of extreme and rights-violating forms of state power is 
integral to many states’ responses to drugs. By focusing on five key 
policies - the death penalty, extrajudicial killings,15 militarisation, life 
imprisonment, and non-consensual confinement in drug treatment 
centres - the Index illustrates how responses to drugs substantially 
diverge across countries, and how some states continue to engage 
in the most brutal forms of the so-called ‘war on drugs’. While no 
country included in the Index reached a score of 100/100, 4 countries 
(Morocco, Norway, Senegal and the United Kingdom) were given more 
than 90/100 in this dimension, while the median score across the 30 
countries is 76/100. At the same time, a cluster of 4 countries (Brazil, 
Indonesia, Mexico and Thailand) diverge significantly from this trend, 
falling under the 50/100 threshold. 
The median score for this dimension is notably higher than for other 
dimensions, which reflects both a focus on the most egregious forms 
of state violence, and the fact that countries automatically receive 
higher scores for many indicators reflected in this dimension simply by 
not enacting a specific policy or response.
The death penalty for drug offences
Reflecting a long-standing global trend towards the abolition of 
the death penalty, only 3 out of the 30 countries included in the 
Index (India, Indonesia and Thailand) retain capital punishment for 
drug offences. The death penalty for drug offences is contrary to 
international human rights standards, which ban capital punishment 
for all but the ‘most serious’ offences, that is crimes of extreme 
gravity involving intentional killing.16
Within this small group of countries, India and Thailand are regarded 
as ‘low-application’ countries, having executed no person convicted 
primarily for a drug offence in the past 5 years, and imposing death 
sentences at a comparatively lower rate.17 In contrast, Indonesia is 
the only ‘high-application’ country covered by the Index - with an 
estimated 214 people on death row for drug offences in 2020.18
15 Extrajudicial killings are summary executions or unnecessary uses of lethal force by state 
agents, including police and the army, but excluding killings by non-state actors
16 See amongst others: Human Rights Council (2019), Resolution 42/24. The question of the 
death penalty, A/HRC/RES/42/24, https://undocs.org/A/HRC/RES/42/24; and Human Rights 
Committee (2018), General comment No. 36 (2018) on article 6 of the International Covenant on 
Civil and Political Rights, on the right to life, CCPR/C/ GC/36, para. 35,
https://tbinternet.ohchr.org/Treaties/CCPR/Shared%20Documents/1_Global/CCPR_C_
GC_36_8785_E.pdf 
17 Harm Reduction International (2021), Death Penalty for Drug Offeces: Global Overview 2020, 
https://www.hri.global/death-penalty-2020
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Prevalence of extrajudicial 
killings in connection to drug 
control
Extrajudicial killings by military and law 
enforcement agents in connection to drug control 
are reported in 50% of the countries surveyed 
in the Index. In 7 countries (Argentina, Canada, 
India, Jamaica, Russia, South Africa and Uganda) 
the unnecessary use of lethal force has been 
recorded in up to 3 cases in 2020, but is perceived 
as a rare occurrence. In an additional 6 countries 
(Afghanistan, Colombia, Indonesia, Lebanon, Kenya, 
and Thailand), extrajudicial killings are considered 
to be a regular, but not widespread, feature of local 
drug enforcement, with up to 20 cases reported in 
2020. In Mexico, extrajudicial killings are regarded 
as widespread, while Brazil stands alone in the 
Index as a country where the unnecessary use of 
lethal force in drug law enforcement is seen as 
endemic - with more than 40 cases in 2020 alone.
The militarisation of drug 
control
The militarisation of drug control activities has 
historically been associated with an increased risk 
of human rights violations and excessive use of 
force, and raises broader political and institutional 
concerns with regards to the role of the military 
in society.19 Strikingly, 27 out of the 30 countries 
included in this edition of the Index have indicated 
that the army or special security forces play some 
role in the enforcement of drug laws. 
In 5 of the countries surveyed in the Index 
(Brazil, Colombia, Kyrgyzstan, Mexico and North 
Macedonia), the involvement of the military or 
special security forces in drug control operations 
is perceived as endemic to the country’s approach 
to drug law enforcement. In 9 additional countries 
(Afghanistan, Costa Rica, Ghana, Jamaica, Kenya, 
Lebanon, Nepal, Russia and Uganda), military and 
special security forces are regularly involved in 
drug law enforcement, with between 20 and 40 
instances reported in 2020 - while in yet another 10 
countries (Argentina, Hungary, Indonesia, Morocco, 
Mozambique, Portugal, Senegal, South Africa and 
Thailand) that involvement was regarded to be 
frequent, with between 3 and 20 interventions in 
2020. In the remaining 7 countries, the involvement 
of the military was reported as either rare or 
completely nonexistent (the latter applying to New 
Zealand, Norway and the United Kingdom).
Prevalence of life sentencing
The imposition of life imprisonment for drug 
offences is an extreme form of disproportionate 
sentencing that constitutes an arbitrary deprivation 
of liberty.20 16 out of the 30 legal frameworks 
surveyed in the Index - just over 50% of the 
countries - do not envisage life sentencing for 
drug-related activities. The Index also shows, 
however, that some of these countries still retain 
very harsh punishments, including prison sentences 
of up to 25 years - as is the case in Mexico and 
South Africa, amongst others.
When it comes to drug use and possession for 
19 Centro de Estudios Legales y Sociales (2018), How the fight against drugs is militarizing Latin America
 https://www.cels.org.ar/militarizacion/en.html
20 UN Working Group on Arbitrary Detention (2021), Arbitrary detention relating to drug policies, A/HRC/47/40, 
https://undocs.org/A/HRC/47/40
‘[People from] the middle and upper classes receive one treatment, while in the favela you can be murdered 
at any time because the favela is considered a “territory of trafficking”. I’m affected by this war daily. Every 
day, and most of the time, there is always an atmosphere of apprehension and anguish. People are always 
in mourning, there is always a neighbour who has had a child murdered. And then the favela goes all silent; 
because it’s in mourning’
Dayana Rosa, Adviser of the Brazilian Network for Harm Reduction and Human Rights (REDUC) - Brazil
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personal use, the Index shows that in practice 24 
out of the 30 surveyed countries never impose 
life sentences. Kenya stands alone as the only 
country where that extreme punishment happens 
frequently for such activities - between 11 and 30% 
of all cases. In the remaining 5 countries where 
drug use or possession for personal use can be 
met with life imprisonment (Ghana, Indonesia, 
Nepal, Thailand and Uganda), this is a rare or very 
rare occurrence.
Just as is the case with capital punishment, 
the imposition of life imprisonment for drug 
supply activities reveals a fracture in countries’ 
approaches to drugs. According to the Index, in 16 
out of the 30 surveyed countries life sentencing 
is either excluded from the law books or never 
imposed, while in 10 countries that happens rarely 
or very rarely. However, the imposition of life 
imprisonment for supply activities is described 
as frequent (in 16 to 30% of cases) in Nepal and 
Thailand, and as very frequent (in 41 to 80% of 
all cases) in Indonesia and Lebanon. In these four 
countries, life sentences are imposed without the 
possibility of parole. 
Non-consensual confinement 
in drug treatment centres
The involuntary confinement of people who use 
drugs in drug treatment centres is a widespread 
phenomenon. It can take different forms across 
the world, from administrative detention in prison-
like compulsory drug detention centres, to court-
mandated inpatient treatment, or involuntary 
internment in private ‘rehabilitation’ centres where 
people who use drugs are brought by their families. 
In all of these cases, involuntary confinement 
constitutes an arbitrary deprivation of liberty,21 as 
detention is not an appropriate response to drug 
use and drug dependence, and drug treatment 
should always be voluntary. Furthermore, many of 
these centres fail to provide harm reduction and 
evidence-based drug treatment, and some have 
been linked to acts of torture and ill-treatment.22
Again, the Index shows significant differences 
between the surveyed countries. On the one 
hand, in 5 countries (Georgia, Kyrgyzstan, 
Morocco, Senegal and the United Kingdom), the 
widely-agreed perception is that non-consensual 
confinement does not take place. On the other 
21 Ibid. 
22 International Drug Policy Consortium (2021), Torture in private ‘rehab’ centres: Submission to the UN Special Rapporteur on Torture,
https://idpc.net/publications/2021/05/submission-to-the-un-special-rapporteur-on-torture-on-the-accountability-gap-for-torture-and-ill-
treatment-in-private-drug-treatment-centres
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23 See amongst others: UN Working Group on Arbitrary Detention (2021), Arbitrary detention relating to drug 
policies, A/HRC/47/40,
 https://undocs.org/A/HRC/47/40 ; UNAIDS (2020), A joint UN statement calls on UN Member States to 
permanently close compulsory drug detention and rehabilitation centres, https://www.unaids.org/en/20200601_
AP_UN_statement ; UNODC & WHO (2021), International standards for the treatment of drug use disorders,
 https://www.unodc.org/documents/drug-prevention-and-treatment/UNODC-WHO_International_
Standards_Treatment_Drug_Use_Disorders_April_2020.pdf 
hand, in 4 other countries (Afghanistan, Brazil, Thailand and Uganda) the 
involuntary internment of people who use drugs in treatment centres is seen 
as a widespread and regular occurrence, while in Mexico it is regarded as an 
endemic part of the system. In the middle, 20 countries report non-consensual 
confinement to a small or moderate extent. All in all, it remains the case that, 
in 25 of the 30 countries included in the Index, some people who use drugs are 
deprived of liberty against their will in the name of ‘drug treatment’, and against 
international normative guidance and human rights standards.23
‘Let the country know about our plights; we do not enjoy this kind of life, need 
support, and have been injured several times (showing a big scar on her knee) 
through police raids in the “ghettos”. We suffer daily under the police; we are 
always their targets’
Gifty, on her experience with police violence as a person involved in drug use and 
selling - Ghana
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Proportionality of the 
criminal justice response
The concept of proportionality is an internationally recognised legal 
principle,24 requiring that the severity of any punishment imposed 
be measured in accordance with the harms caused by the person’s 
actions, and the culpability and circumstances of the person having 
committed the offence. Overall, countries scored poorly regarding 
the proportionality of their criminal justice response related to drug 
control, with a median score of just 34/100. Apart from Australia, 
Costa Rica, Jamaica, New Zealand, Portugal and the United Kingdom, 
all countries scored below 50/100 - with Kenya and Uganda being 
allocated particularly low scores at 13/100 and 17/100, respectively. 
Human rights violations in the criminal 
justice system
Worryingly, the Index data emphasizes the widespread human rights 
abuses committed in the name of drug control within the criminal 
justice apparatus, including acts of violence and torture committed 
by the police and arbitrary arrests and detention, with only a handful 
of countries reporting these acts as rare occurrences. In Afghanistan, 
Kenya and Kyrgyzstan, for instance, violent acts by the police were 
perceived to be widespread in drug control efforts, while these were 
considered to be rare (or very rare) occurrences in only 6 countries 
(Costa Rica, Hungary, New Zealand, North Macedonia, Norway and 
the United Kingdom). Similarly, cases of arbitrary detention were 
considered as being rare in only 3 of the 30 surveyed countries: New 
Zealand, Portugal and the United Kingdom. 
With regards to fair trial rights25 for people suspected of drug 
offences, the possibility of being guaranteed a fair trial was 
considered as unlikely in Afghanistan, with substantial restrictions in 
access to a fair trial reported in 12 countries: Georgia, Ghana, Kenya, 
Kyrgyzstan, Mexico, Morocco, Mozambique, Nepal, North Macedonia, 
Russia, Thailand and Uganda. Access to a fair trial was perceived as 
being guaranteed in only 7 countries: Australia, Canada, Costa Rica, 
New Zealand, Norway, Portugal and the United Kingdom. 
24 International Centre on Human Rights and Drug Policy, Office of the High Commissioner for 
Human Rights, UNAIDS, World Health Organization & United Nations Development Programmes 
(2019), International guidelines on human rights and drug policy, 
https://www.undp.org/publications/international-guidelines-human-rights-and-drug-policy 
25 A fair trial includes the following components: no arbitrary arrests take place, the courts are 
competent, independent and impartial; and hearings and trials generally follow arrest and charge 
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Disproportionate impacts of 
the criminal justice response
The United Kingdom, however, is amongst the 
countries scoring the lowest with regards to the 
impacts of the criminal justice response on specific 
groups, alongside Brazil, Mexico, Russia and others. 
Equity within the criminal justice response was 
perceived as one of the most disregarded aspects 
of drug policy in government responses, with only 
5 countries being scored above 50/100, and the 
highest-ranking countries (Afghanistan, Kyrgyzstan 
and Senegal) only reaching a maximum of 67/100. 
The disproportionate impact of drug control on 
low-income groups was reported in every single 
country covered by the Index. With regards to 
perceived discriminations on the grounds of 
ethnicity and gender, several countries were 
singled out as scoring particularly poorly. Regarding 
ethnicity, countries like Brazil, Canada, Mexico, 
Nepal, South Africa and the United Kingdom scored 
particularly low, whereas the gendered impacts 
of drug control were reported as a trend in all 
Latin American countries covered by the Index 
(Argentina, Brazil, Colombia, Costa Rica and Mexico) 
as well as in Kenya, India, Indonesia, Russia, South 
Africa and Uganda. 
Furthermore, criminal justice resources were 
perceived as being mainly focused on people 
prosecuted for non-violent drug offences. Indeed, 
no country received more than 50/100 on this 
thematic cluster, and over a third of the countries 
were given a score of 0/100. This shows how those 
generally targeted by drug control efforts are the 
‘low-hanging fruit’ - non-violent, low-level actors 
in the illegal drug market (such as people who use 
drugs) rather than those involved in violent and/or 
organised criminal activity.
Decriminalisation and 
alternatives to prison and 
punishment
The high numbers of people incarcerated for 
non-violent drug offences can be explained, in 
part, by the fact that drug use and possession for 
personal use remain criminalised in most countries 
worldwide. Only 8 out of 30 countries reported 
some form of decriminalisation of drug use and 
possession for personal use in their legal system26 
- Colombia, Costa Rica, Jamaica, Kyrgyzstan, 
Mexico, Portugal, Russia and South Africa, in 
addition to Australia and India having such policies 
at subnational level (it should be noted that in India 
the decriminalisation policy extends exclusively 
to the state of Sikkim, which represents less than 
1% of the country’s total population). While Costa 
Rica, Kyrgyzstan, Portugal and Russia and the state 
of Sikkim in India reported having decriminalised 
all drugs, others like Australian states, Jamaica 
and South Africa only decriminalised the use and 
possession of cannabis. 
The Index showcases wide differences in terms 
of implementation of decriminalisation in those 
8 countries. Strikingly, decriminalisation was only 
perceived as truly diverting people away from 
the criminal justice system in Colombia, Jamaica 
and Portugal, and perceived as having entirely 
failed against this metric in Mexico, Kyrgyzstan, 
Russia and South Africa (although for South 
Africa this might be explained by the fact that the 
decriminalisation system is still being established 
after the Constitutional Court judgment of 2018, 
and focuses exclusively on cannabis, rather than 
all substances). Finally, although criminal sanctions 
were removed in these 8 countries, administrative 
sanctions imposed within the decriminalised policy 
were reported as being severe in countries like 
26 Decriminalisation refers to the removal of criminal penalties for drug use and related activities, such as the possession of drugs, the possession 
of drug use equipment, as well as the cultivation and purchase of drugs for personal consumption. See: www.idpc.net/decriminalisation 
‘The stigma of being a family member of a person who is deprived of their liberty is intense; but it becomes even 
more so as a result of the total absence of guidance from the Costa Rican penitentiary system’
Giselle Amador, member of the International network of women family members of people deprived of their 
liberty (RIMUF) - Costa Rica
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Colombia, Kyrgyzstan and Russia - hampering the 
key objective of decriminalisation, which should be 
to stop punishing people for drug use and related 
activities.
In addition to decriminalisation, the Index 
evaluates governments’ performance regarding 
the availability and use of alternatives to arrest, 
prosecution, conviction and/or punishment for 
drug-related activities. Australia, Jamaica, New 
Zealand, North Macedonia and Portugal were 
given the highest score (85/100) in the provision of 
alternatives to arrest, prosecution, conviction and/
or punishment, with those ranking the lowest being 
Colombia, Georgia, Kenya, Morocco, Mozambique 
and Uganda.
It is generally best for alternatives to prison and 
punishment to be applied as early as possible 
within people’s journey through the criminal justice 
system. However, although all countries covered by 
the Index have provisions within their legislation for 
such alternatives (although no actual alternative 
is available in practice in Mozambique), most of 
them (24 countries) provide these options at the 
moment of sentencing, while less than half provide 
alternatives at the point of arrest and before 
conviction. Only 9 countries (Australia, Costa Rica, 
Jamaica, Kyrgyzstan, Mexico, New Zealand, North 
Macedonia, Portugal and Russia) were found to 
provide alternatives at all three stages.
The types and quality of the alternatives on offer 
also vary greatly from country to country. While 
most countries (except for Colombia, Georgia, 
Kenya, Kyrgyzstan, Morocco and Uganda) offer 
treatment and care as alternatives for people who 
use drugs caught in the criminal justice system, 
they all retain the possibility of imposing prison or 
punishment if the person does not attend or fails 
to complete treatment, or restarts or continues 
using drugs. Even more worryingly, only 11 countries 
offer a range of treatment options based on 
people’s needs and preferences (Afghanistan, 
Australia, Canada, Ghana, Hungary, Jamaica, New 
Zealand, North Macedonia, Portugal, Senegal and 
the United Kingdom). 
of 30 
countries
Decriminalised drug use 
and possession for personal 
use at national level
Decriminalised all drugs Showed that their 
decriminalisation model 
successfully diverts 
people away from the 
criminal justice system
8 of 30 countries4 of 30 countries3
‘Because I’m a drug user, I know what’s “wrong” with drug users: They are always insulted and humiliated. 
Every time, [authorities] come [and capture] drug users, they beat them. Criminalisation does not allow us to 
help our community’
Abdur Raheem Rejaey, Head of Bridge Hope Health Organization, a community-led organisation providing 
peer support - Afghanistan
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Mandatory minimum sentencing and 
pretrial detention
Finally, the Index explores the use of mandatory minimum sentencing 
and pretrial detention for people accused of drug-related offences - both 
considered as key drivers of incarceration and prison overcrowding. Only 
Australia, Jamaica, Lebanon, New Zealand, Norway and South Africa 
reached the perfect score of 100/100 in this area (i.e. no mandatory 
minimum penalties or mandatory use of pretrial detention for drug 
offences). While no country studied within the Index has mandatory pretrial 
detention within its drug laws, it is highly concerning that 24 countries 
have mandatory minimum penalties for drug-related offences that can be 
applied for first-time offences (with the exception of the United Kingdom 
which applies mandatory minimums for multiple offences only).
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Health and harm reduction 
With a median score of 40/100 and 20 countries under the 50 point 
divide, the Index highlights a dramatic dearth of life-saving harm 
reduction services across the world. The level of investment in harm 
reduction is considered as adequate in only 5 out of the 30 countries. 
While harm reduction interventions are nominally present in most of 
the surveyed states, the Index shows an alarming lack of availability 
and coverage across the board.
Harm reduction in national policy 
documents
The Index shows that national strategies and policy documents have 
paid increasing attention to harm reduction and people who use drugs. 
Encouragingly, all but 5 of the countries (Brazil, Indonesia, Jamaica, 
Mozambique and Russia) have explicit supportive references to harm 
reduction in national policy documents, while all but 6 countries 
(Brazil, Canada, Hungary, Indonesia, Jamaica and Mozambique) refer 
to people who use drugs as a key vulnerable population in their 
national HIV strategies. Significantly lower scores are achieved when 
it comes to referring to people who use drugs as target populations in 
strategies related to hepatitis C and tuberculosis, where they are only 
mentioned in 12 and 10 cases, respectively. 
However, this relative progress underscores that commitments on 
paper do not guarantee secure and sustainable access to harm 
reduction services in reality. For the 3 countries that have achieved a 
score of 100/100 on the policy side (Afghanistan, Lebanon and Mexico), 
the Index also reports very low funding for harm reduction services, 
and limited or very limited availability of harm reduction interventions 


































‘My lived experience in problematic drug use and as a beneficiary 
of the harm reduction programme in Kenya have been among my 
motivations in working to challenge the processes and stringent 
policies that catalyse the cycle of stigmatisation and discrimination 
that leads to a lack of access to health services for people who use 
drugs’
Anami Michael, Kenyan human rights and drug policy change activist 
- Kenya
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Lack of sustainable funding for 
harm reduction
The Index confirms the overall dearth of 
sustainable funding for harm reduction. Considering 
the countries’ estimated needs, harm reduction 
services have secured an ‘adequate’ level of 
investment in only 5 out of the 30 countries 
surveyed (Canada, New Zealand, Norway, Portugal 
and the United Kingdom), with Australia following 
suit with reports of ‘moderately adequate’ funding. 
In 13 of the remaining 24 countries, investment in 
harm reduction is estimated to fall into the ‘very 
low’ category - reinforcing claims of a continuing 
global crisis when it comes to harm reduction 
funding.27
Of the highest-scoring countries for this metric, the 
current investment in harm reduction is considered 
to be ‘mostly secure’ in just one country (Norway). 
Funding was considered to be either likely to be 
reduced in Canada, uncertain in New Zealand, 
Portugal and the United Kingdom, or somewhat 
unstable in Australia.
Of the settings with insufficient levels of harm 
reduction funding, the outlook for the next 3 to 5 
years is regarded as uncertain or somewhat unstable 
in 12 countries, while additional budget cuts are 
seen as likely in a further 12 countries, and severe 
reductions are already anticipated in 4 countries 
(Jamaica, Hungary, Kyrgyzstan and Russia). 
Availability and coverage of 
harm reduction interventions
With a median score of 33/100, and 24 countries 
unable to reach 50/100 in this sub-dimension, the 
Index confirms the alarming lack of availability 
and coverage of harm reduction interventions. 
The Index also reveals an overlap between the 
countries that have scored more than 50/100 
(Afghanistan, Australia, Canada, Norway, Portugal 
and the United Kingdom), and those where 
investment was reported as ‘adequate’ - further 
reinforcing the need for sustainable funding for 
harm reduction.
In a majority of countries there is at least one 
operational NSP and OAT programme. All but 6 
countries (Argentina, Brazil, Costa Rica, Ghana, 
Jamaica and Uganda) host at least one NSP, but 
in 19 out of these 24 countries coverage is either 
limited or very limited, which means that less 
than 200 syringes per person who uses drugs are 
distributed each year. For countries like Argentina, 
Brazil, Costa Rica and Jamaica, it should be 
noted that opioid use and drug injection are less 
prevalent, which can partially explain the lack of 
availability of NSPs and OAT. This, however, should 
not be seen as an excuse for failing to ensure 
adequate access to harm reduction interventions 
on the ground for people who use stimulant drugs 
and other substances.28
27 Failure To Fund: The continued crisis for harm reduction funding in low- and middle-income countries. Harm Reduction International, 2021. 
https://www.hri.global/failure-to-fund
28 For more information, see, for instance: United Nations Office on Drugs and Crime, World Health Organization & UNAIDS (2019), HIV 
prevention, treatment, care and support for people who use stimulant drugs - Technical guide,  https://www.unodc.org/documents/hiv-aids/
publications/People_who_use_drugs/19-04568_HIV_Prevention_Guide_ebook.pdf 
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Following a similar pattern, all but 7 countries 
(Brazil, Costa Rica, Ghana, Jamaica, Mozambique, 
Russia and Uganda) host one operational OAT site 
- but in 19 out of these 23 countries coverage is 
either limited or very limited, meaning that this 
intervention is estimated to reach no more than 
39% of the population that needs it. The peer 
distribution of naloxone (also called ‘take-home 
naloxone’), an opioid antagonist that can reverse 
the effects of an overdose, is operational in 7 
countries - Afghanistan, Australia, Canada, India, 
Mexico, New Zealand and the United Kingdom. 
However, the coverage of naloxone distribution 
programmes for people who use opioids was 
considered to be over 40% in only 3 countries - 
Canada, Norway and the United Kingdom. Up to 19 
countries had at least one drug checking service, 
which allow people who use drugs to identify the 
components in the substances they intend to take. 
However, coverage of these services was reported 
to be ‘very limited’ in 15 countries, and ‘limited’ in 
the remaining 4. Lastly, only 4 countries (Australia, 
Canada, Norway and Portugal) were reported to 
have at least one operational drug consumption 
room, even though evidence shows that the 
use of supervised drug consumption facilities is 
associated with reducing drug-related deaths, and 
are effective at reaching out to highly marginalised 
populations.29
Although states are obliged to fulfil the right to 
health of people deprived of liberty, including the 
right to access harm reduction services, the Index 
shows that the availability of these interventions 
in prisons is even more restricted than in the 
community. Only 1 country (Canada) has NSP 
provision in prison settings, though coverage is 
very limited. 15 out of the 30 surveyed countries 
provide OAT services in prisons, but in practice only 
3 countries (North Macedonia, Portugal and the 
United Kingdom) have secured access to OAT for 
more than 40% of people who use drugs in prison.
Perception of inequity in 
accessing harm reduction 
services
The Index also seeks to capture national experts’ 
perception on the barriers to accessing harm 
reduction services attributable to ethnicity, gender 
identity and sexual orientation. To some degree, 
these inequities are perceived as being present in 
the overwhelming majority of countries. 
According to civil society experts, ethnicity was 
reported as having no impact on access to harm 
reduction in only 5 out of the 30 surveyed countries 
(Georgia, India, Kyrgyzstan, North Macedonia and 
Norway). On the contrary, members of specific 
ethnic groups were perceived as having experienced 
disparities in accessing harm reduction to a large 
or very large extent in 7 out of the 30 countries 
(in Australia, Brazil, Canada, Ghana, Mexico, New 
Zealand and Thailand). 
Similarly, women and LGBTQI+ people are 
considered to face heightened and differential 
obstacles in accessing harm reduction in every 
single surveyed country, in particular (to a large 
or very large extent) in 9 out of 30 countries 
(Argentina, Brazil, Colombia, Costa Rica, Ghana, 
Mexico, Portugal, South Africa and Uganda).
Strikingly, many of the wealthier countries in which 
harm reduction services are more available and 
well-funded score relatively low for this sub-
dimension, including: the United Kingdom (49/100), 
New Zealand (41/100s), Portugal (41/100), Canada 
(33/100) and Australia (33/100) - compared to the 
overall median score of 49/100. 
29 European Monitoring Centre for Drugs and Drugs Addiction (2018), Drug consumption rooms: an overview of provision and evidence, 
https://www.emcdda.europa.eu/publications/pods/drug-consumption-rooms_en
‘You’re under the watchful eye (without being stared at!) of a nurse, just to make sure you’re not in the throes of 
overdose. Because this is a medically-supervised injection centre; emphasis on medically. No one dies here. No 
one has died. And it’s been 19 years running. So...well done!’
Kevin, Former client of Sydney’s Medically Supervised Injecting Centre (MSIC) - Australia
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Experts’ perception of equity in
















Access to, and availability 
of,  internationally controlled 
medicines for the relief 
of pain and suffering 
Ensuring access to, and availability of, internationally controlled 
medicines30 for the relief of pain and suffering is one of the key 
objectives of the UN drug control conventions.31 Yet, the Index 
confirms the general acknowledgement that there are wide 
differences on how well countries are doing in ensuring such access, 
with country scores ranging from 21/100 for Uganda all the way to 
81/100 for Norway - and a median score of 41/100.
Recognising the importance of access to 
controlled medicines in national policies
On the policy side, it is encouraging that all countries surveyed in the 
Index, with the exception of Kenya and Morocco, have explicit provisions 
within their national legislation or policy documents establishing their 
government’s obligation to ensure access to controlled medicines. 
Unfortunately, only about half of the countries studied in the Index also 
have a national medicines policy that recognises the importance of 
availability of controlled medicines for pain relief.
Even more problematically, the data show that only a handful of 
countries ensure the meaningful involvement of key stakeholders - 
such as medical boards, health professionals, patients and patients’ 
representatives - in policy-making processes related to controlled 
medicines. Nepal and New Zealand were the only two countries 
singled out as doing particularly well in this area, as opposed to 
Russia where involvement was reported as non-existent.
30 A ‘controlled medicine’ is a psychoactive substance, the production, sale, possession and use 
of which is restricted to those authorised by the international drug control regime
31 United Nations General Assembly (2016), Outcome document of the 2016 United Nations 
General Assembly Special Session on the World Drug Problem: Our joint commitment to effectively 



































‘Nothing gives me more satisfaction as a nurse than providing pain 
relief to a suffering patient and family’
Rose Kiwanuka, Uganda’s first palliative care nurse - Uganda
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Assessing access to controlled 
medicines for those in need
Importantly, beyond looking into policy documents 
the Index evaluates states’ perceived performance 
in ensuring actual availability and access for 
people on the ground. The results are damning, 
with over two-thirds of the countries covered in 
the Index receiving a score of 38/100 or under. 
While countries like Australia, New Zealand, 
Norway, Portugal and the United Kingdom seem 
to ensure adequate access and availability for 
those in need, Ghana, India, Indonesia, Mexico, 
Mozambique, Nepal, Senegal and Uganda were 
given the lowest possible score of 0/100. In two-
thirds of the countries evaluated, the global 
consumption of opioids was reported as being low 
or very low. 
Two main considerations can be drawn from 
these data. Firstly, the Index highlights the major 
disparities in access to controlled medicines 
between ‘Global North’ countries and those based 
in the ‘Global South’, in particular in terms of 
availability of opioid medicines. Research shows 
that the dearth of controlled medicines is driven at 
least in part by weak and under-funded healthcare 
systems, as much as by unduly restrictive legal 
frameworks.32 Secondly, the Index underscores 
the worrying gap between existing policies and 
their implementation, with most countries scoring 
reasonably well on the policy side, but performing 
badly in terms of ensuring actual access to 
controlled medicines for people in need. 
Perceived discriminations in 
access to controlled medicines 
for specific groups
In addition to disparities between countries, the 
Index shows large differences in access within 
each country. Major geographical disparities in 
access were reported in countries like Brazil, 
Canada, Colombia, Kenya, Kyrgyzstan, Mexico, 
Mozambique, Nepal, Russia, South Africa and 
Uganda. Socio-economic status was perceived 
as being a discriminatory factor in accessing 
controlled medicines in over half of the countries 
evaluated, with only Costa Rica and Portugal 
being the exception in that regard. To a lesser 
extent, people from specific gender and ethnic 
groups were also reported as having poorer access 
to controlled medicines, with Brazil, Canada, 
Colombia, Hungary, Mexico and New Zealand 
scoring especially poorly on restrictions in access 
based on ethnicity, and Uganda and Jamaica 
being singled out as countries where women have 
particularly poor access to controlled medicines. 
Finally, the Index assesses the extent to which 
people who use drugs are able to access 
controlled medicines for pain relief to the same 
level as other groups. In 12 countries (Australia, 
Brazil, Canada, Colombia, Jamaica, Kyrgyzstan, 
Lebanon, Mexico, Nepal, Norway, South Africa and 
Uganda), people who use drugs were perceived 
as facing major barriers in accessing controlled 
medicines for pain relief compared to others in 
society. Georgia, Ghana and Senegal were the 
only countries where no such disparities in access 
were reported by civil society experts. This is yet 
another example of how people who use drugs 
continue to be stigmatised and discriminated 
against in access to basic healthcare.
32Global Commission on Drug Policy (2015), The Negative Impact of Drug Control on Public Health: The Global Crisis of Avoidable Pain, 
http://www.globalcommissionondrugs.org/wp-content/uploads/2012/03/GCODP-THE-NEGATIVE-IMPACT-OF-DRUG-CONTROL-ON-PUBLIC-HEALTH-EN.pdf  
33 Pereira, I. & Ramírez Bolívar, L. (2019), Los caminos del dolor: Acceso a cuidados paliativos y tratamiento por consumo de heroína en Colombia, 
https://www.dejusticia.org/publication/los-caminos-del-dolor-acceso-a-cuidados-paliativos-y-tratamiento-por-consumo-de-heroina-en-colombia/ 
‘He was going to pass away regardless; but with a bit of support from the healthcare authorities, it would have 
all been a bit easier on us’
Anonymous, on the experience of supporting their father after he was denied buprenorphine patches to manage 




Perceived disparities in access to controlled medicines
Discriminations in access to controlled medicines reported to a large or very large extent in:
15 of 30 countries12 of 30 countries11 of 30 countries6
on the basis of 
socio-economic 
status
on the basis of  
of drug use
on the basis of  
geographical 
location
on the basis of 
ethnicity




The Global Drug Policy Index 2021
54
Development 
The ‘development’ dimension of the Index is used for countries where 
there are alternative or sustainable development policies in place in 
areas where crops are cultivated for illegal drug production. In this first 
iteration of the Index, this includes Afghanistan, Colombia, Jamaica and 
Thailand - while for the other 26 countries, the development dimension 
was omitted from their overall score calculations.34
Alternative development, which seeks to eliminate the cultivation of 
crops destined for illegal markets by addressing the vulnerabilities of the 
communities involved in growing them, has been widely criticised over the 
past decades for taking an overly narrow approach to ‘development’, placing 
too much focus on eradication while failing to genuinely address the needs 
and vulnerabilities of communities on the ground.35 These concerns are 
reflected in the findings of the Index, with countries scoring particularly 
poorly on this dimension. Thailand, with the highest score of the four, only 
achieved 48/100, and Colombia scored a mere 23/100. 
A narrow approach to development
The Index highlights how alternative development remains entrenched 
in an interdiction and eradication approach to illegal crop cultivation, 
without sufficiently taking into consideration the development needs 
of communities on the ground. On paper, Colombia and Thailand are 
reported as placing some emphasis on broader development dimensions 
within their alternative development policy - with Thailand reaching 
a score of 63/100 - but neither country takes into consideration 
the protection of the environment within their policy. By contrast, 
Afghanistan fails to enshrine its alternative development programme 
within a broader development approach, but its programme does 
include some provisions related to environmental protection. 
Even more concerning is the fact that the alternative development 
policy in both Colombia (‘to a very large extent’) and Afghanistan (‘to 
a moderate extent’) are operating within a militarised and security 
strategy. Both countries place strong emphasis on forced crop 
eradication, including - in the case of Colombia - via aerial spraying, 
which can cause serious harm for local communities, health and the 
34 For more information, please read the Methodology: globaldrugpolicyindex.net/methodology
35 See, for instance: Nougier, M., Cots Fernandez, A. & Putri, D. (2021), Taking stock of half a 








‘Most people who grow cannabis in the mountains of Zihuatanejo live in 
unfavourable conditions. Some people do not have running water. Draft 
legislation must 100% include rural communities to promote employment’
Arturo, veterinarian and cannabis grower - Mexico
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Summary table of alternative development policy and its impact on vulnerable groups
Afghanistan Colombia Jamaica Thailand
AD* embedded in 
development  policy
Absence of forced crop 
eradication in AD policy
Absence of aerial spraying
Adequate sequencing
Involvement of local 
communities in AD policy
Impacts on the empowerment 
of women
Impacts on young people












Limited Limited LimitedTo a large extent
environment. Both Jamaica and Thailand fare 
much better in this area, achieving a score of 72/100, 
as neither country has provisions for forced crop 
eradication within their alternative development policy. 
Another strong criticism of existing alternative 
development programmes relates to their failure 
to ensure adequate sequencing - that is, ensuring 
that alternative livelihoods are in place for local 
communities before starting any eradication 
effort. This is a key aspect of a development 
approach in areas of illegal cultivation. There 
again, with the exception of Afghanistan (‘to a 
moderate extent’), adequate sequencing was only 
taken into consideration ‘to a small extent’ in 
Colombia, Jamaica and Thailand. 
Perceptions on the involvement 
of affected communities
The involvement of affected communities (such as 
farmers of crops used for illegal drug production) 
in alternative development programmes is 
essential to ensure that these programmes truly 
respond to their needs, take into consideration 
their preferences, local customs, knowhow and 
skills, and are grounded in an understanding of 
the local land and ecosystem. Worryingly, the 
Index shows that local communities and (where 
appropriate) Indigenous and minority groups were 
perceived as being meaningfully involved in the 
design, implementation, monitoring and evaluation 
of alternative development programmes only to 
a ‘moderate extent’ in Thailand, and to a ‘small 
extent’ in Afghanistan, Colombia and Jamaica.  
Limited perceived benefits for 
communities on the ground
The militarised and security approach to alternative 
development, the focus on forced eradication, the 
lack of consideration of development needs, the 
failure to ensure adequate sequencing and the lack 
of involvement of local communities have inevitably 
hampered meaningful and positive outcomes for 
alternative development programmes. Indeed, an 
assessment of the impacts on communities on the 
ground by civil society experts shows a mixed and 
complex picture in that regard, with Afghanistan 
scoring the highest of the 4 countries with 57/100. 
In recent years, alternative development programmes 
have sought to improve the conditions of women 
as key beneficiaries. The Index shows that this was 
only perceived as being achieved ‘to a large extent’ in 
Afghanistan, with limited progress made in Colombia, 
Jamaica and Thailand. Similarly, the benefits of 
alternative development programmes on young people 
and on low-income groups were reported as moderate 
in Afghanistan, but limited in all 3 other countries.
‘Peaceful letters have been written. Demonstrations have been made. A lot of dialogue has taken place. But the ganja 
industry remains in the hands of the rich people; without those who have suffered being able to benefit’
Ras Iyah V, Rastafari cannabis activist and human rights defender - Jamaica




















USE OF EXTREME SENTENCING AND RESPONSES






PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 18
Equity of impact of criminal justice response 66
Mandatory minimum sentencing and pre-trial detention 37
Alternatives to arrest, prosecution, conviction and punishment 59
Extent of imprisonment of individuals involved in non-violent drug-related offences 25
Decriminalisation 0
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 100
Harm reduction funding 0
Harm reduction intervention availability and coverage 52
Equity of access to harm reduction services 49
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 84
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 38
Equity of Access to controlled medicines for the relief of pain and suffering 56
DEVELOPMENT
Alternative development policy design 29
Management of crop eradication 48
Efficacy of alternative development policy for key beneficiaries 57
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 
SUBSTANCES FOR THE RELIEF OF PAIN AND SUFFERING
DEVELOPMENT




















*Please note that data collection via the expert civil society survey was conducted as the military offensive by the Taliban was unfolding in Afghanistan in 
August 2021. Inevitably, this major crisis caused considerable difficulties for local civil society experts to be able to respond to the survey, resulting in many 
responses coming from experts living outside of Afghanistan. This might explain the fact that perceptions on certain drug policy issues covered by the Index 
for the period 2020 might seem to be overly positive compared to how similar issues were perceived and scored by local civil society in other countries
‘Because I’m a drug user, I know what’s “wrong” with drug users. They are always insulted and humiliated. Every time, [authorities] 
come [and capture] drug users, they beat them. Criminalisation does not allow us to help our community’ 
 
~Abdur Raheem Rejaey, Head of Bridge Hope Health Organization, a community-led organisation providing peer support














USE OF EXTREME SENTENCING AND RESPONSES






PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 41
Equity of impact of criminal justice response 8
Mandatory minimum sentencing and pre-trial detention 37
Alternatives to arrest, prosecution, conviction and punishment 56
Extent of imprisonment of individuals involved in non-violent drug-related offences 0
Decriminalisation 0
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 74
Harm reduction funding 0
Harm reduction intervention availability and coverage 10
Equity of access to harm reduction services 32
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 75
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 25
Equity of Access to controlled medicines for the relief of pain and suffering 62
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 
SUBSTANCES FOR THE RELIEF OF PAIN AND SUFFERING
DEVELOPMENT




















‘The worst thing was when we had health issues. I have dentition issues and there wasn’t a dentist at the detention centre. 
Accessing medical consultations required cumbersome paperwork and, even when you managed to be seen, the person 
doing the checkup wasn’t always a doctor or a specialist. On more than one occasion I was seen by other incarcerated 
people, who “prescribed” ibuprofen’
 
~Rubí, on her experience as a trans woman prosecuted for drug supply charges that she contends are fabricated















USE OF EXTREME SENTENCING AND RESPONSES






PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 59
Equity of impact of criminal justice response 25
Mandatory minimum sentencing and pre-trial detention 100
Alternatives to arrest, prosecution, conviction and punishment 85
Extent of imprisonment of individuals involved in non-violent drug-related offences 25
Decriminalisation 33
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 74
Harm reduction funding 61
Harm reduction intervention availability and coverage 64
Equity of access to harm reduction services 33
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 51
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 75
Equity of Access to controlled medicines for the relief of pain and suffering 44
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















‘You’re under the watchful eye (without being stared at!) of a nurse, just to make sure you’re not in the throes of overdose. 
Because this is a medically-supervised injection centre; emphasis on medically. No one dies here. No one has died. And it’s 
been 19 years running. 
 So...well done!’
 
~Kevin, ex-client of Sydney’s Medically Supervised Injecting Centre (MSIC)
median from the 30 countries 














USE OF EXTREME SENTENCING AND RESPONSES






PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 33
Equity of impact of criminal justice response 0
Mandatory minimum sentencing and pre-trial detention 37
Alternatives to arrest, prosecution, conviction and punishment 44
Extent of imprisonment of individuals involved in non-violent drug-related offences 0
Decriminalisation 0
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 14
Harm reduction funding 0
Harm reduction intervention availability and coverage 2
Equity of access to harm reduction services 24
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 75
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 12
Equity of Access to controlled medicines for the relief of pain and suffering 24
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















‘[People from] the middle and upper classes receive one treatment, while in the favela you can be murdered at any time 
because the favela is considered a “territory of trafficking”. I’m affected by this war daily. Every day, and most of the time, 
there is always an atmosphere of apprehension and anguish. People are always in mourning, there is always a neighbour 
who has had a child murdered. And then the favela goes all silent; because it’s in mourning’
 
~Dayana Rosa, Adviser of the Brazilian Network for Harm Reduction and Human Rights (REDUC)
median from the 30 countries 















USE OF EXTREME SENTENCING AND RESPONSES






PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 59
Equity of impact of criminal justice response 17
Mandatory minimum sentencing and pre-trial detention 37
Alternatives to arrest, prosecution, conviction and punishment 59
Extent of imprisonment of individuals involved in non-violent drug-related offences 25
Decriminalisation 0
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 35
Harm reduction funding 61
Harm reduction intervention availability and coverage 72
Equity of access to harm reduction services 33
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 84
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 62
Equity of Access to controlled medicines for the relief of pain and suffering 24
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















‘When overdoses happen on-site [at the community centre], there is this mandate that you call the emergency [services]; 
that you call 911. Oftentimes, when 911 is called, cops come as well. One time, I think someone overdosed in the bathroom. 
EMS was called and along with the EMS came the police. We understood that cops were going to come through. And when 
cops come through, everything goes wrong. When cops come through, the probability that the substance user, the person of 
colour will make it out alive is a lot slimmer’
 
~Akia Munga, activist challenging the opioid emergency, and Blacktivist ‘with a capital B’
median from the 30 countries 
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PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 41
Equity of impact of criminal justice response 24
Mandatory minimum sentencing and pre-trial detention 37
Alternatives to arrest, prosecution, conviction and punishment 32
Extent of imprisonment of individuals involved in non-violent drug-related offences 0
Decriminalisation 73
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 87
Harm reduction funding 0
Harm reduction intervention availability and coverage 24
Equity of access to harm reduction services 41
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 84
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 24
Equity of Access to controlled medicines for the relief of pain and suffering 37
DEVELOPMENT
Alternative development policy design 38
Management of crop eradication 9
Efficacy of alternative development policy for key beneficiaries 23
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















‘[To leave prison] is to start again, but from zero, from many zeroes. After my release, it felt as if I had been blindfolded; I 
didn’t know where to go, what to do, and, to be honest, right now I don’t know which doors I have left to knock on’
 
~Martha Merchán, formerly incarcerated woman and primary caregiver for her seven children
median from the 30 countries 
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PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 58
Equity of impact of criminal justice response 16
Mandatory minimum sentencing and pre-trial detention 37
Alternatives to arrest, prosecution, conviction and punishment 70
Extent of imprisonment of individuals involved in non-violent drug-related offences 25
Decriminalisation 82
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 74
Harm reduction funding 0
Harm reduction intervention availability and coverage 4
Equity of access to harm reduction services 32
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 84
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 38
Equity of Access to controlled medicines for the relief of pain and suffering 70
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















‘The stigma of being a family member of a person who is deprived of their liberty is intense; but it becomes even more so as a 
result of the total absence of guidance from the Costa Rican penitentiary system’
 
~Giselle Amador, member of the International network of women family members of people deprived of their liberty (RIMUF)
median from the 30 countries 
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PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 33
Equity of impact of criminal justice response 50
Mandatory minimum sentencing and pre-trial detention 37
Alternatives to arrest, prosecution, conviction and punishment 32
Extent of imprisonment of individuals involved in non-violent drug-related offences 0
Decriminalisation 0
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 74
Harm reduction funding 31
Harm reduction intervention availability and coverage 41
Equity of access to harm reduction services 66
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 42
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 50
Equity of Access to controlled medicines for the relief of pain and suffering 75
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















‘Despite the fact that no drugs were proven to be present in my body, every time I came across police officers in the street, 
there would always be attempts at harassing me. (...) Nowadays, the inhumane acts of drug testing practices have almost 
fully been eliminated in the country. Nevertheless, the state is still repressive...’ 
 
~Temo Khatiashvili, on past experiences of police harassment due to criminal records in relation to drug use
median from the 30 countries 















USE OF EXTREME SENTENCING AND RESPONSES






PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 16
Equity of impact of criminal justice response 42
Mandatory minimum sentencing and pre-trial detention 37
Alternatives to arrest, prosecution, conviction and punishment 59
Extent of imprisonment of individuals involved in non-violent drug-related offences 25
Decriminalisation 0
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 48
Harm reduction funding 0
Harm reduction intervention availability and coverage 0
Equity of access to harm reduction services 8
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 42
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 0
Equity of Access to controlled medicines for the relief of pain and suffering 75
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















‘I have tried several rehabilitation houses, but it has not worked for me; they are not female-friendly and they are too 
expensive’
 
~Gifty, on the challenges of finding support for drug dependence
median from the 30 countries 
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PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 66
Equity of impact of criminal justice response 25
Mandatory minimum sentencing and pre-trial detention 37
Alternatives to arrest, prosecution, conviction and punishment 59
Extent of imprisonment of individuals involved in non-violent drug-related offences 50
Decriminalisation 0
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 21
Harm reduction funding 11
Harm reduction intervention availability and coverage 32
Equity of access to harm reduction services 49
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 42
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 50
Equity of Access to controlled medicines for the relief of pain and suffering 50
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















‘I have always suffered abuse because of my Roma origin and drug use. After the accident, I had to go back for regular 
check-ups. Every time I went to the hospital, I would get comments from patients like: ‘oh, the “junkie” is here’. I would also 
hear it from the hospital staff sometimes, although they didn’t say it to my face’ 
 
~Tamás, on navigating formal support systems after surviving a life-threatening physical assault during his time using drugs 
in the streets
median from the 30 countries 
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PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 41
Equity of impact of criminal justice response 41
Mandatory minimum sentencing and pre-trial detention 37
Alternatives to arrest, prosecution, conviction and punishment 44
Extent of imprisonment of individuals involved in non-violent drug-related offences 25
Decriminalisation 37
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 87
Harm reduction funding 1
Harm reduction intervention availability and coverage 46
Equity of access to harm reduction services 66
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 75
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 0
Equity of Access to controlled medicines for the relief of pain and suffering 49
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















median from the 30 countries 














USE OF EXTREME SENTENCING AND RESPONSES






PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 33
Equity of impact of criminal justice response 24
Mandatory minimum sentencing and pre-trial detention 37
Alternatives to arrest, prosecution, conviction and punishment 44
Extent of imprisonment of individuals involved in non-violent drug-related offences 25
Decriminalisation 0
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 0
Harm reduction funding 1
Harm reduction intervention availability and coverage 36
Equity of access to harm reduction services 49
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 75
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 0
Equity of Access to controlled medicines for the relief of pain and suffering 42
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















‘They bound my arms [and] my legs to a tree and they tied me. I tried to get them to let me out because it hurt… I’m not a bad 
person. I just need help with my addiction. But they didn’t listen’ 
 
~Rosma Karlina, Women’s Program Coordinator at AKSI Keadilan Indonesia*
* Quote taken from: Karlina, R., ‘Women who use drugs - I was one of them…’, Voice Global, https://voice.global/blog/women-who-use-drugs/
median from the 30 countries 















USE OF EXTREME SENTENCING AND RESPONSES






PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 50
Equity of impact of criminal justice response 33
Mandatory minimum sentencing and pre-trial detention 100
Alternatives to arrest, prosecution, conviction and punishment 85
Extent of imprisonment of individuals involved in non-violent drug-related offences 50
Decriminalisation 76
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 27
Harm reduction funding 0
Harm reduction intervention availability and coverage 2
Equity of access to harm reduction services 58
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 51
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 25
Equity of Access to controlled medicines for the relief of pain and suffering 37
DEVELOPMENT
Alternative development policy design 29
Management of crop eradication 72
Efficacy of alternative development policy for key beneficiaries 23
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















‘Peaceful letters have been written. Demonstrations have been made. A lot of dialogue has taken place. But the ganja 
industry remains in the hands of the rich people; without those who have suffered being able to benefit’ 
 
~Ras Iyah V, Rastafari cannabis activist and human rights defender
median from the 30 countries 














USE OF EXTREME SENTENCING AND RESPONSES






PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 8
Equity of impact of criminal justice response 8
Mandatory minimum sentencing and pre-trial detention 37
Alternatives to arrest, prosecution, conviction and punishment 30
Extent of imprisonment of individuals involved in non-violent drug-related offences 0
Decriminalisation 0
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 74
Harm reduction funding 21
Harm reduction intervention availability and coverage 37
Equity of access to harm reduction services 58
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 8
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 12
Equity of Access to controlled medicines for the relief of pain and suffering 55
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















‘My lived experience in problematic drug use and as a beneficiary of the harm reduction programme in Kenya have 
been among my motivations in working to challenge the processes and stringent policies that catalyse the cycle of 
stigmatisation and discrimination that leads to a lack of access to health services for people who use drugs’ 
 
~Anami Michael, human rights and drug policy change activist
median from the 30 countries 















USE OF EXTREME SENTENCING AND RESPONSES






PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 17
Equity of impact of criminal justice response 59
Mandatory minimum sentencing and pre-trial detention 37
Alternatives to arrest, prosecution, conviction and punishment 56
Extent of imprisonment of individuals involved in non-violent drug-related offences 0
Decriminalisation 57
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 74
Harm reduction funding 0
Harm reduction intervention availability and coverage 30
Equity of access to harm reduction services 74
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 75
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 12
Equity of Access to controlled medicines for the relief of pain and suffering 50
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















‘After I was released [from the penal colony], I decided that I would stop using heroin and opium. I switched to cannabis to 
facilitate the transition. One day, I was walking with a friend and my child. The police stopped us and took us to the police 
station. I spent half a year in pre-trial detention. My friend was sentenced to 4 years in prison’ 
 
~Olga now works as an outreach worker and street lawyer, sharing her knowledge of the law with women who use drugs
median from the 30 countries 














USE OF EXTREME SENTENCING AND RESPONSES






PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 33
Equity of impact of criminal justice response 33
Mandatory minimum sentencing and pre-trial detention 100
Alternatives to arrest, prosecution, conviction and punishment 44
Extent of imprisonment of individuals involved in non-violent drug-related offences 25
Decriminalisation 0
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 100
Harm reduction funding 0
Harm reduction intervention availability and coverage 38
Equity of access to harm reduction services 75
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 84
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 25
Equity of Access to controlled medicines for the relief of pain and suffering 43
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















median from the 30 countries 















USE OF EXTREME SENTENCING AND RESPONSES






PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 16
Equity of impact of criminal justice response 0
Mandatory minimum sentencing and pre-trial detention 37
Alternatives to arrest, prosecution, conviction and punishment 70
Extent of imprisonment of individuals involved in non-violent drug-related offences 0
Decriminalisation 64
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 100
Harm reduction funding 0
Harm reduction intervention availability and coverage 31
Equity of access to harm reduction services 16
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 75
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 0
Equity of Access to controlled medicines for the relief of pain and suffering 24
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















‘Most people who grow cannabis in the mountains of Zihuatanejo live in unfavourable conditions. Some people do not have 
running water. Draft legislation must 100% include rural communities to promote employment’ 
 
~Arturo, veterinarian and cannabis grower
median from the 30 countries 














USE OF EXTREME SENTENCING AND RESPONSES






PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 33
Equity of impact of criminal justice response 41
Mandatory minimum sentencing and pre-trial detention 37
Alternatives to arrest, prosecution, conviction and punishment 30
Extent of imprisonment of individuals involved in non-violent drug-related offences 50
Decriminalisation 0
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 48
Harm reduction funding 31
Harm reduction intervention availability and coverage 39
Equity of access to harm reduction services 58
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 17
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 25
Equity of Access to controlled medicines for the relief of pain and suffering 69
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















median from the 30 countries 















USE OF EXTREME SENTENCING AND RESPONSES






PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 25
Equity of impact of criminal justice response 41
Mandatory minimum sentencing and pre-trial detention 37
Alternatives to arrest, prosecution, conviction and punishment 18
Extent of imprisonment of individuals involved in non-violent drug-related offences 25
Decriminalisation 0
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 14
Harm reduction funding 0
Harm reduction intervention availability and coverage 16
Equity of access to harm reduction services 58
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 42
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 0
Equity of Access to controlled medicines for the relief of pain and suffering 63
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















‘Eight months after starting the opioid agonist therapy programme (with methadone), my life started changing. I stopped 
using heroin and my outlook on life improved. I felt accepted in society and by my family, which helped me improve my self-
esteem’ 
 
~Jaime, 30-year-old security technician and OST client of a drop-in centre in Maputo
median from the 30 countries 














USE OF EXTREME SENTENCING AND RESPONSES






PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 25
Equity of impact of criminal justice response 25
Mandatory minimum sentencing and pre-trial detention 37
Alternatives to arrest, prosecution, conviction and punishment 44
Extent of imprisonment of individuals involved in non-violent drug-related offences 50
Decriminalisation 0
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 48
Harm reduction funding 21
Harm reduction intervention availability and coverage 30
Equity of access to harm reduction services 49
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 59
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 0
Equity of Access to controlled medicines for the relief of pain and suffering 36
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















median from the 30 countries 















USE OF EXTREME SENTENCING AND RESPONSES






PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 84
Equity of impact of criminal justice response 25
Mandatory minimum sentencing and pre-trial detention 100
Alternatives to arrest, prosecution, conviction and punishment 85
Extent of imprisonment of individuals involved in non-violent drug-related offences 50
Decriminalisation 0
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 87
Harm reduction funding 71
Harm reduction intervention availability and coverage 42
Equity of access to harm reduction services 41
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 92
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 88
Equity of Access to controlled medicines for the relief of pain and suffering 50
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















median from the 30 countries 














USE OF EXTREME SENTENCING AND RESPONSES






PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 50
Equity of impact of criminal justice response 25
Mandatory minimum sentencing and pre-trial detention 37
Alternatives to arrest, prosecution, conviction and punishment 85
Extent of imprisonment of individuals involved in non-violent drug-related offences 25
Decriminalisation 0
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 48
Harm reduction funding 31
Harm reduction intervention availability and coverage 42
Equity of access to harm reduction services 66
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 42
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 63
Equity of Access to controlled medicines for the relief of pain and suffering 75
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















median from the 30 countries 















USE OF EXTREME SENTENCING AND RESPONSES






PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 75
Equity of impact of criminal justice response 42
Mandatory minimum sentencing and pre-trial detention 100
Alternatives to arrest, prosecution, conviction and punishment 58
Extent of imprisonment of individuals involved in non-violent drug-related offences 25
Decriminalisation 0
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 74
Harm reduction funding 91
Harm reduction intervention availability and coverage 65
Equity of access to harm reduction services 66
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 84
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 88
Equity of Access to controlled medicines for the relief of pain and suffering 69
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















‘While being held in a[n isolation] cell [for the possession of two cannabis joints], I missed my therapy session. This 
experience was devastating to me. I felt stigmatised, dehumanised and discriminated against by the police and the 
government. Being labeled a criminal in what was a very vulnerable time for me in my life was very hard. I experienced 
increased anxiety and depression, which again led me to increased and more dangerous use of illegal substances as a form 
of self-medication’ 
 
~André Nielsen, Chair of NORML Norge
median from the 30 countries 














USE OF EXTREME SENTENCING AND RESPONSES






PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 68
Equity of impact of criminal justice response 41
Mandatory minimum sentencing and pre-trial detention 37
Alternatives to arrest, prosecution, conviction and punishment 85
Extent of imprisonment of individuals involved in non-violent drug-related offences 50
Decriminalisation 88
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 74
Harm reduction funding 71
Harm reduction intervention availability and coverage 58
Equity of access to harm reduction services 41
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 51
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 75
Equity of Access to controlled medicines for the relief of pain and suffering 70
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















‘In June 2020, I applied to work in a mobile drug consumption room (MDCR) since I had experience with injecting drugs. I 
became a peer worker and had my first real contact with harm reduction and with services that were not sobriety based. 
I’ve learned more about drugs and consumption in this last year than I’ve done my whole life; even after engaging with 
drugs for more than 14 years’ 
 
~João Caldas, peer worker at GAT - Grupo de Ativistas em Tratamentos
median from the 30 countries 















USE OF EXTREME SENTENCING AND RESPONSES






PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 16
Equity of impact of criminal justice response 16
Mandatory minimum sentencing and pre-trial detention 37
Alternatives to arrest, prosecution, conviction and punishment 70
Extent of imprisonment of individuals involved in non-violent drug-related offences 0
Decriminalisation 63
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 79
Harm reduction funding 0
Harm reduction intervention availability and coverage 12
Equity of access to harm reduction services 58
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 34
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 12
Equity of Access to controlled medicines for the relief of pain and suffering 49
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















median from the 30 countries 














USE OF EXTREME SENTENCING AND RESPONSES






PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 33
Equity of impact of criminal justice response 67
Mandatory minimum sentencing and pre-trial detention 37
Alternatives to arrest, prosecution, conviction and punishment 59
Extent of imprisonment of individuals involved in non-violent drug-related offences 0
Decriminalisation 0
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 74
Harm reduction funding 21
Harm reduction intervention availability and coverage 34
Equity of access to harm reduction services 58
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 84
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 0
Equity of Access to controlled medicines for the relief of pain and suffering 75
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















‘Had the CEPIAD been opened earlier, so many lives would have been saved’ 
 
~Ousseynou Ndiaye, on his experience with Dakar’s Centre for the Integrated Management of Addiction (CEPIAD), which 
provides opioid agonist treatment
median from the 30 countries 















USE OF EXTREME SENTENCING AND RESPONSES






PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 32
Equity of impact of criminal justice response 8
Mandatory minimum sentencing and pre-trial detention 100
Alternatives to arrest, prosecution, conviction and punishment 44
Extent of imprisonment of individuals involved in non-violent drug-related offences 0
Decriminalisation 57
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 87
Harm reduction funding 11
Harm reduction intervention availability and coverage 27
Equity of access to harm reduction services 32
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 42
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 12
Equity of Access to controlled medicines for the relief of pain and suffering 44
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















‘Both the community-based work and the research that I’m involved in on a daily basis give meaning to my life’ 
 
~MJ Stowe, member of the South African Network of People who Use Drugs (SANPUD), on the value of being of service for his 
community
median from the 30 countries 














USE OF EXTREME SENTENCING AND RESPONSES






PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 33
Equity of impact of criminal justice response 33
Mandatory minimum sentencing and pre-trial detention 37
Alternatives to arrest, prosecution, conviction and punishment 44
Extent of imprisonment of individuals involved in non-violent drug-related offences 25
Decriminalisation 0
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 48
Harm reduction funding 21
Harm reduction intervention availability and coverage 22
Equity of access to harm reduction services 41
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 42
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 25
Equity of Access to controlled medicines for the relief of pain and suffering 42
DEVELOPMENT
Alternative development policy design 63
Management of crop eradication 72
Efficacy of alternative development policy for key beneficiaries 23
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















‘Looking back it was terrible... a very terrible experience. It’s a pretty horrible 10 days. We were counting down the days 
every single day. I guess I could say that most people there are poor. It’s as if the centre was built specifically for them. But if 
you ask me whether they deserve this or not, I don’t think they deserve to be in here no matter what their social status is’ 
 
~21-year-old young adult that underwent ‘drug rehabilitation’ in a centre run by the military in Thailand*
* Quote taken from: Nougier, M., Cots Fernandez, A. & Putri, D. (2021), Taking stock of half a decade of drug policy: An evaluation of UNGASS 
implementation, http://fileserver.idpc.net/library/UNGASS_5y_Review.pdf
median from the 30 countries 















USE OF EXTREME SENTENCING AND RESPONSES






PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 16
Equity of impact of criminal justice response 24
Mandatory minimum sentencing and pre-trial detention 37
Alternatives to arrest, prosecution, conviction and punishment 30
Extent of imprisonment of individuals involved in non-violent drug-related offences 0
Decriminalisation 0
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 21
Harm reduction funding 0
Harm reduction intervention availability and coverage 4
Equity of access to harm reduction services 32
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 42
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 0
Equity of Access to controlled medicines for the relief of pain and suffering 37
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















‘Nothing gives me more satisfaction as a nurse than providing pain relief to a suffering patient and family’ 
 
~Rose Kiwanuka, Uganda’s first registered palliative care nurse*
* Segment from a statement delivered by Ms. Rose Kiwanuka, Country Director, Palliative Care Association of Uganda (PCAU), on the occasion of the 
Forth Intersessional Meeting of the 59th Commission on Narcotic Drugs, 10 October 2016, Vienna, Austria,  https://www.unodc.org/documents/
postungass2016/contributions/NGO/Statement_Ms._Rose_Kiwanuka_PCAU_Uganda.pdf UNGASS_5y_Review.pdf
median from the 30 countries 














USE OF EXTREME SENTENCING AND RESPONSES






PROPORTIONALITY OF THE CRIMINAL JUSTICE RESPONSE
Human rights violations 84
Equity of impact of criminal justice response 17
Mandatory minimum sentencing and pre-trial detention 66
Alternatives to arrest, prosecution, conviction and punishment 73
Extent of imprisonment of individuals involved in non-violent drug-related offences 50
Decriminalisation 0
HEALTH AND HARM  REDUCTION
Extent to which state policy prioritises harm reduction for people who use drugs 74
Harm reduction funding 71
Harm reduction intervention availability and coverage 62
Equity of access to harm reduction services 49
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED SUBSTANCES FOR PAIN RELIEF
Policy prioritisation of availability and accessibility of controlled medicines for the relief 
of pain and suffering 51
De facto availability and accessibility of controlled medicines for the relief of pain and suffering 88
Equity of Access to controlled medicines for the relief of pain and suffering 56
DEVELOPMENT
Alternative development policy design n/a
Management of crop eradication n/a
Efficacy of alternative development policy for key beneficiaries n/a
PROPORTIONALITY OF CRIMINAL JUSTICE RESPONSE
HEALTH AND HARM REDUCTION
AVAILABILITY OF AND ACCESS TO INTERNATIONALLY CONTROLLED 





















median from the 30 countries 
